Gene therapy-based strategies for glioblastoma towards chemosensitization : use of gemini surfactants as drug delivery systems by Cruz, Ana Rita Queirós da
 
 
Ana Rita Queiroz da Cruz 
 
 
 
 
 
 
 
Gene Therapy-Based Strategies for 
Glioblastoma Towards Chemosensitization: 
Use of Gemini Surfactants as Drug Delivery 
Systems 
 
 
 
 
 
 
 
 
Dissertação apresentada à Universidade de Coimbra para 
cumprimento dos requisitos necessários à obtenção do grau de 
Mestre em Biotecnologia Farmacêutica. 
 
 
 
 
 
Coimbra 
Setembro, 2015 
ii 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Front Cover: RNA silencing. 
http://losnuevosguerreros.org/mod/glossary/view.php?id=93&mode=date&hook=&sortkey=U
PDATE&sortorder=asc&fullsearch=0&page=12 
iii 
 
This work was performed at the Center for Neuroscience and Cell Biology, University of 
Coimbra, Portugal, in the Group of Vectors and Gene Therapy, under the supervision of 
Professor Maria Amália da Silva Jurado, Professor Maria da Conceição Monteiro Pedroso de 
Lima and Professor Luís Fernando Morgado Pereira de Almeida. 
 
 
 
 
 
 
 
This work is funded by FEDER funds through the Operational Programme Competitiveness 
Factors - COMPETE and national funds by FCT - Foundation for Science and Technology 
under the strategic project UID/NEU/04539/2013. 
 
 
 
 
 
 
 
 
 
 
 
 
 
iv 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
v 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Toda a ciência está aqui, 
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A 
AAV - adeno-associated virus 
ABC - ATP-binding cassette 
Ad - adenovirus 
AGO2 - Argonaute 2 
 
B 
BBB - blood-brain barrier 
BII - Bliss interaction index 
BIR - baculoviral IAP repeat domain 
BIRC5 - baculoviral IAP repeat containing 
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bis-quats - bis-quaternary ammonium salts 
 
C 
CDDP - cisplatin 
cDNA - complementary DNA 
CGS - cationic gemini surfactants 
CMC - critical micellar concentrations  
CMV - cytomegalovirus 
CNS - central nervous system 
CSC - cancer stem cells 
D 
DLS - dynamic light scattering 
DOPE - dioleoylphosphatidylethanolamine 
dsRNA - double-stranded RNA 
 
E 
EGFR - epidermal growth factor receptor 
ETO - etoposido 
 
F 
FDA - Food and Drug Administration 
 
G 
GBM - glioblastoma 
GFP - green fluorescent protein 
 
H 
HII - inverted hexagonal phase 
HL - helper lipids 
HPRT1- hypoxanthine 
phosphoribosyltransferase 1 
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I 
IAP - inhibitor-of-apoptosis proteins 
 
L 
Lo - liquid-ordered 
 
M 
MET - mesenchymal-epithelial transition 
MGMT - O6-methylguanine-DNA 
methyltransferase 
miRNAs - microRNAs 
MLV - multilamellar vesicles 
MMP - mitochondria-penetrating peptides 
mRNA - messenger RNA 
MRP2, cMOAT or ABCC2 - multidrug 
resistance-associated protein 2 
mtDNA - mitochondrial DNA 
MTS - mitochondrial targeting sequences 
 
N 
ncDNA - nuclear DNA 
NER - nucleotide excision repair 
NRT - no reverse transcription control 
NTC - No Template Control 
P 
PCS - photon correlation spectroscopy 
PDGFR - platelet-derived growth factor 
receptors 
pDNA - plasmid DNA 
PE - phosphatidylethanolamines 
pmtGFP - plasmid DNA encoding 
mitochondrial GFP 
pncGFP - plasmid DNA encoding nuclear 
GFP 
 
Q 
QELS - quasi-elastic light scattering  
qRT-PCR - quantitative real time PCR 
 
R 
Rb - retinoblastoma protein 
RISC - RNA-induced silencing complex 
RNAi - RNA interference 
Rv - retrovirus 
 
S 
siGFP - siRNA duplex against GFP 
siRNA DY547 - DY547 labeled non-
targeting siRNA duplex  
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siRNAs - small interfering RNAs 
siSURV - anti-survivin siRNA duplex  
siMUT - non-targeting siRNA duplex  
SRB - sulforhodamine B 
 
T 
TKR - receptor tyrosine kinase 
TMZ – temozolomide 
Topo IIa - Topoisomerase Iia 
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W 
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Resumo 
O glioblastoma é o tipo de tumor cerebral mais comum e agressivo, caraterizando-se por 
alta capacidade proliferativa, elevados níveis de angiogénese e grande resistência à 
quimioterapia. O tratamento médico habitual envolve a remoção do tecido tumoral através 
de cirurgia, seguida de radioterapia com concomitante ou subsequente administração do 
agente alquilante temozolomida (TMZ). No entanto, a evolução clínica está longe de ser 
satisfatória, sendo a taxa de sobrevivência média dos doentes de apenas 15 meses após o 
diagnóstico. Tendo em consideração que a maior causa de insucesso do tratamento desta 
patologia reside na resistência intrínseca e adquirida aos fármacos, este trabalho teve por 
principal objectivo o desenvolvimento de estratégias terapêuticas capazes de sensibilizar as 
células de GBM a agentes quimioterapêuticos. Com este propósito, foram implementadas 
duas estratégias de terapia génica não-viral, envolvendo o uso de tensioativos gemini 
catiónicos (CGS) e explorando o seu potencial para a vectorização de ácidos nucleicos e 
fármacos. Numa das estratégias foram utilizados CGS como vectores de siRNAs em células 
humanas de glioblastoma (U87), a fim de diminuir a expressão da proteína anti-apoptótica 
survivina, sobre-expressa em tecidos tumorais, e aumentar, consequentemente, a 
susceptibilidade das células a agentes quimioterapêuticos. A segunda estratégia usufruiu da 
vantagem dos GSC promoverem a transferência de pDNA tanto para o núcleo como para as 
mitocôndrias de células de uma linha de glioblastoma estabelecida a partir de um tumor 
recorrente (DBTRG-05MG), e explorou a capacidade desses mesmos sistemas de entrega 
induzirem a libertação, em ambos os organelos, do fármaco anticancerígeno cisplatina 
(CDDP), cuja ação farmacológica envolve a formação de aductos com moléculas de DNA. 
Neste trabalho ficou patente que a redução da expressão de survivina potencia 
sinergisticamente a acção tóxica dos compostos TMZ e etopósido nas células U87. Por 
outro lado, a exposição de células DBTRG-05MG a CDDP incorporada em complexos de 
pDNA e tensioativos gemini derivados de serina conduziu a uma diminuição drástica da 
viabilidade e da proliferação das células, bem como à paragem do ciclo celular na fase S, 
efeitos que mostraram ser mais severos do que os induzidos por CDDP na forma livre, na 
mesma concentração. Adicionalmente, o pDNA usado como veículo de CDDP, complexado 
com tensioativos gemini, demonstrou não ter perdido a capacidade de promover expressão 
génica, quando transferido para o núcleo ou para a mitocôndria. Desta forma, as estratégias 
implementadas neste estudo revelaram a possibilidade de reduzir as doses terapêuticas de 
fármacos anticancerígenos, contribuindo para prevenir o desenvolvimento de 
quimiorresistência e obviar efeitos colaterais dos fármacos. Além disso, demonstrando a 
versatilidade e o elevado potencial das formulações contendo tensioativos gemini para a 
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vectorização de ácidos nucleicos e fármacos em células de GBM, este estudo abre caminho a 
abordagens terapêuticas multi-modais que, aliando a quimioterapia à terapia génica, 
permitem vencer com elevada eficiência a quimiorresistência de GBM. 
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Abstract 
Glioblastoma (GBM) is the most common and aggressive primary brain tumor, being 
characterized by its propensity for proliferation, strong angiogenesis and resistance to 
chemotherapy. The standard treatment involves maximal surgical resection, radiotherapy 
and adjuvant or concomitant administration of the alkylating drug temozolomide (TMZ). 
However, the clinical outcome has proven to be far from being satisfactory, patients having a 
median survival of only 15 months after diagnosis. Taking into account that the major cause 
of treatment failure in GBM patients is the intrinsic and acquired drug resistance, the 
objective of the present work was centered in the development of therapeutic strategies 
aiming at sensitizing GBM cells to chemotherapeutics. To accomplish this objective, two 
gene therapy-based approaches were developed, involving the use of cationic gemini 
surfactants (CGS) and exploiting their potential for drug delivery. The first strategy took 
advantage of the ability of CGS to deliver siRNA, in order to promote downregulation of the 
anti-apoptotic protein survivin, aberrantly expressed in tumor tissues, so that GBM cells 
(U87) become more susceptible to chemotherapeutics. The second strategy benefited from 
the potential of GCS to deliver pDNA into nucleus and mitochondria in human recurrent 
glioblastoma cells (DBTRG-05MG), exploring their capacity to promote in both organelles a 
co-delivery of the anti-cancer drug cisplatin (CDDP), whose pharmacological activity is based 
on the formation of adducts with DNA molecules.  
Significant results were obtained showing that survivin knockdown combined with 
temozolomide or etoposide administration resulted in a synergistic toxic effect on U87 cells. 
Additionally, the delivery of CDDP formulated in serine-derived gemini surfactant-based 
complexes led to a drastic decrease of viability of DBTRG-05MG cells, an efficient inhibition 
of cell growth and a significant arrest of the cell cycle in the S phase, effects that showed to 
be much more severe than those induced by free CDDP, at the same concentrations. 
Moreover, it was observed that the pDNA, used as a vehicle of CDDP formulated in gemini 
surfactant-based complexes, did not lose its capacity to promote gene expression, when 
delivered both in the nucleus and in mitochondria. 
Therefore, both strategies implemented in this study revealed the possibility of reducing the 
doses of anti-cancer drugs to prevent the emergence of chemoresistance and drug side-
effects. Additionally, benefiting from the versatility and potential of gemini surfactant-based 
formulations for drug delivery in GBM cells, this study opens windows towards the 
establishment of multimodal therapeutic approaches, allying chemotherapeutics to gene 
therapy, aiming at surpassing the chemoresistance of GBM.  
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 1 
 
 Introduction 
8 
 
Introduction 
 
1.1. Glioblastoma 
The central nervous system (CNS) is composed of two types of cells: neurons (or nerve 
cells) and neuroglia (or glia), the latter being three times more abundant than the former. 
Physically, glial cells are similar to neurons, but their less prolonged branches do not have 
the same functions as axons and dendrites. Neurons are responsible for receiving, 
processing and sending electrical signals, through synaptic interactions. Glial cells support 
neurons’ functions: preserve the ionic milieu of nervous system, modulate signal 
transmission, synaptic action and neural development, and also assist the recovery of injured 
neurons (Purves et al., 2004). Glial cells can be divided into three cell types: astrocytes, 
oligodendrocytes and microglial cells. 
Tumors that arise from glial cells are named gliomas and the ones that emerge from 
astrocytes (astrocytomas) are the most common form of glioma, accounting for 75% of all 
primary CNS gliomas (Adamson et al., 2009). Glioblastoma (GBM), which is classified by the 
World Health Organization (WHO) as a grade IV glioma, being therefore the most 
malignant and challenging astrocytoma to treat, represents > 51% of all primary CNS gliomas 
(Adamson et al., 2009). The etiology of gliomas is still unknown, but two risk factors have 
been pointed as possible causes for their development: the exposure to high doses of 
ionizing radiation and hereditary mutations associated with syndromes such as Cowden’s 
disease, Li–Fraumeni syndrome and neurofibromatosis (Adamson et al., 2009; Schwartzbaum 
et al., 2006). The most common symptoms of GBM are progressive focal neurologic deficits, 
headaches, and seizures (Adamson et al., 2009). 
 
1.1.1. Grading  
WHO grading, which is a “malignancy scale” based on the histology of tumors of the CNS, 
when combined with other parameters such as age, tumor location, proliferation rate and 
genetic alterations, allows to predict the neoplasm behavior, establish a prognosis, choose 
the appropriate therapy and predict the response to this therapy (Louis et al., 2007). Table 
1.1 shows the WHO grading of astrocytic gliomas, the predictive prognosis and neoplasm 
behavior. 
Besides the four WHO grades, in which gliomas are divided, two different classes of 
astrocytic gliomas are considered regarding their capacity for invasion and propensity for 
malignancy progression: diffuse astrocytic tumors, which include WHO grades II, III and IV 
that are described as tumors with a high potential for invasion, with diffuse infiltration, and 
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with a propensity to develop into higher grades of malignancy; and low grade infiltrative 
astrocytomas, which correspond to WHO grade I and are characterized by their limited 
invasion and propensity for malignancy progression (Ware, Berger and Binder, 2003). 
 
Table 1.1 - WHO grading of astrocytic gliomas Louis et al., 2007; Ware et al., 2003. 
 
WHO 
grading 
 
 
Astrocytic gliomas 
 
 
Prognosis 
 
 
Neoplasm behavior 
 
 
Grade I 
 
juvenile pilocytic 
astrocytoma 
 
 
treatable with 
resection 
 
low proliferation 
 
Grade II 
 
 
diffuse astrocytoma 
 
 
> 5 years 
low proliferation, 
infiltrative, 
nuclear atypia, 
possibility of malignancy 
progression 
 
Grade III 
 
anaplastic astrocytoma 
 
2 – 3 years 
nuclear atypia, 
mitotic activity, 
possibility of malignancy 
progression 
 
Grade IV 
 
glioblastoma 
 
1 year 
nuclear atypia, 
mitotic activity, 
endothelial proliferation, 
necrosis 
 
Based on the origin of the tumor, GBMs can also be classified as primary and secondary 
GBMs. Primary GBM accounts for 90% of all GBM cases, occurring in older patients, and 
arise in an isolated manner, without clinical or histological signals of a previous less malignant 
astrocytoma (Ohgaki and Kleihues, 2007, 2013). Secondary GBM occurs in patients with less 
than 45 years and arises from a lower grade astrocytoma, commonly from WHO grade II, 
which progressively becomes a higher malignancy astrocytoma (WHO grades III or IV) 
(Furnari et al., 2007). Interestingly, their morphology is indistinguishable but their genetic and 
epigenetic profiles reveal differences, which probably indicates that these two classes of 
GBM require different therapeutic strategies (Furnari et al., 2007; Ohgaki and Kleihues, 2007, 
2013). For this reason and also because tumors of the same WHO grade behave differently 
towards therapy, an extensive research has been conducted to identify different 
chromosomal abnormalities, genetic alterations and impaired molecular pathways of the 
astrocytic tumors (Furnari et al., 2007; Ohgaki and Kleihues, 2007; Tanaka et al., 2013; 
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Verhaak et al., 2010). This may allow a more detailed classification of gliomas and also the 
design of new molecular targeted therapies. 
 
1.1.2. Common hallmarks and impaired signaling pathways 
GBM is characterized by uncontrolled cellular proliferation and widespread invasion, 
resistance to apoptosis, strong angiogenesis, and propensity to impair adjacent normal tissue 
(Furnari et al., 2007). In addition, GBM exhibits cellular heterogeneity, presenting a 
subpopulation of cancer stem cells (CSC) that seems to be responsible for tumor resistance 
to chemotherapy. Therefore, GBM patient prognosis remains poor, the disease culminating 
in death 12 to 15 months after diagnosis. 
Genetic alterations, specifically the activation of oncogenes and the downregulation of 
tumor-suppressor genes, have been identified in all types of cancers, as contributors to 
tumor proliferation. A great number of these genetic abnormalities have been found in GBM, 
favoring cell proliferation, cell migration and apoptosis inhibition. These features have been 
correlated with the capability of low grade astrocytic tumors to achieve higher levels of 
malignancy (secondary GBM). 
Regarding GBM molecular expression, GBM can be divided into four subtypes: proneural, 
neural, classical and mesenchymal, and the response to therapy is dependent on the subtype, 
the classical subtype being the most susceptible and the proneural subtype being the most 
resistant (Verhaak et al., 2010). Nevertheless, there are three signaling pathways that are 
proven to be impaired in all subtypes of GBM: the receptor tyrosine kinase (TKR)/Ras/PI3K, 
the retinoblastoma protein (Rb) and p53 signaling (Tanaka et al., 2013). These three 
pathways ensure the balance between cell proliferation and cell death, acting in different 
manners. 
TKR/RAS/PI3K signaling is impaired in 88% of GBM cases (Cancer Genome Atlas Research 
Network, 2008; Tanaka et al., 2013) and the overexpression of the TRK epidermal growth 
factor receptor (EGFR) is present in 40%-50% of patients with GBM (Stommel et al., 2007; 
Tanaka et al., 2013; Ware et al., 2003). Among them, 50% present the EGFRIII variant, which 
causes a constitutive activation of this signaling pathway, leading to cell growth, proliferation 
and survival. Besides EGFR, other TKRs can be amplified, namely platelet-derived growth 
factor receptors (PDGFR) and mesenchymal-epithelial transition (MET) (Snuderl et al., 2011; 
Stommel et al., 2007; Szerlip et al., 2012), which reflects intratumoral heterogeneity (Szerlip 
et al., 2012) and likely results in tumor-resistance to targeted therapies (Stommel et al., 
2007). 
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A high percentage of GBM patients (78%) present Rb signaling impairment. Rb protein 
mediates G1/S cell cycle arrest, and the loss of function of this protein in GBM favors G1/S 
progression and, consequently, cancer development (Cancer Genome Atlas Research 
Network, 2008; Tanaka et al., 2013).  
The p53 signaling pathway is altered in 87% of GBM patients (Cancer Genome Atlas 
Research Network, 2008; Tanaka et al., 2013). In response to DNA damage, the tumor 
suppressor protein p53 causes G1 and/or G2 cell cycle arrest, leading to apoptosis (Tanaka 
et al., 2013). In addition, wild-type p53 downregulates, at the transcriptional level, survivin 
expression, which is one of the nine members of the family of inhibitor-of-apoptosis proteins 
(IAP) (George, Banik and Ray, 2010; Mita et al., 2008). Therefore, due to p53 function 
impairment in GBM, overexpression of survivin is potentiated and, consequently, the cancer 
progresses. 
 
Survivin overexpression 
Survivin is a 16.4-kDa protein encoded by the BIRC5 (baculoviral IAP repeat containing 5) 
gene, which is overexpressed in the majority of cancers, including GBM (George et al., 2010). 
Survivin, the smallest protein of the IAP family, contains a single BIR (baculoviral IAP repeat 
domain) and acts through inhibition of mitochondrial-dependent apoptosis. However, its 
function is not limited to cell death blocking, since it also plays an important role in the 
regulation of mitosis (Okada and Mak, 2004), angiogenesis (Duffy et al., 2007; Ryan, B.; 
O’Donovan, N.; Duffyg, 2009) and chemoresistance (Mita et al., 2008; Pennati, Folini and 
Zaffaroni, 2008).  
After transcription, survivin mRNA undergoes alternative splicing, originating four protein 
variants: wild-type survivin, survivin-2β, survivin-ΔEx3 and survivin-3β. Survivin-2β differs 
from wild-type survivin by an additional exon of 23 amino acids; the lack of the exon 3 
generates survivin-ΔEx3; and survivin-3B results from the addition of an extra exon (exon 
3B) (Caldas et al., 2005; Noton et al., 2006). Therefore, the amino acid sequence of each 
survivin isoform is remarkably different, which has an impact on protein molecular weight 
(Table 1.2), tertiary structure and, probably, on the anti-apoptotic function. Additionally, 
these isoforms have different subcellular locations: survivin, survivin-2β and survivin-3B are 
preferentialy localized in the cytoplasm, while survivin-ΔEx3 is localized in the nucleus 
(Mahotka et al., 2002). 
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Table 1.2 - Features and preferential localization of the four protein isoforms. Adapted 
from Caldas et al., 2005. 
 Survivin Survivin-2β Survivin- ΔEx3 Survivin-3B 
Preferential localization cytoplasm cytoplasm nucleus cytoplasm 
Protein size (aa) 142 165 137 120 
Predicted molecular 
weight (kDa) 
 
16.4 
 
18.6 
 
15.6 
 
13.8 
 
Survivin constitutes an attractive target for cancer therapies because it is rarely detected in 
normal tissues (Altieri, 2008; Duffy et al., 2007; Mita et al., 2008) and is highly expressed in 
tumors (Altieri, 2008), revealing different expression levels of protein isoforms, which can be 
correlated with tumor aggressiveness (Caldas et al., 2005). 
The effect of therapeutic strategies involving survivin silencing on cell death has proven to be 
cell type-dependent (Trabulo et al., 2011). In fact, survivin depletion can suffice for observing 
a cell death phenotype, or can result in cancer cell sensitization to apoptosis by 
chemotherapeutic drugs. In the latter situation, an additional therapy is required to induce 
cell death, a survivin silencing strategy combined with chemotherapy or with another 
targeted therapy being more effective in this case (Mita et al., 2008). 
 
1.1.3. Therapeutic approaches 
The standard treatment for patients with GBM involves maximal surgical resection followed 
by radiotherapy and adjuvant or concomitant temozolomide (TMZ) administration. This 
combined treatment prolongs survival in 2.5 months, when compared with radiotherapy 
alone (Stupp et al., 2005; Zhang, Stevens and Bradshaw, 2012). 
 
Chemotherapy 
a. Temozolomide 
Temozolomide (Figure 1.1) was approved by the Food and Drug Administration (FDA) on 
March, 2005 for treatment of patients with primary GBM (Anton, Baehring and Mayer, 
2012). Currently, TMZ is the first-line chemotherapeutic agent for treating GBM patients. 
Therapies targeting brain tumors have to overcome blood-brain barrier (BBB) to be 
effective, and TMZ, an alkylating agent, can cross the BBB, due to its lipophilicity. TMZ is a 
prodrug that undergoes spontaneous chemical conversion at a physiological pH (Kaina et al., 
2007; Zhang et al., 2012). Its active form subsequently acts through the delivery of a  methyl  
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group  to  the purine  bases  of  DNA, thus methylating O6-guanine,  N7-guanine  and  N3-
adenine, the O6 position of guanine being the main site that upon methylation causes 
cytotoxic lesions (Zhang et al., 2012).  
However, this drug has shown to induce chemoresistance, losing its efficiency to treat GBM 
patients. The main mechanism responsible for the acquired chemoresistance is the increased 
expression of the DNA-repair enzyme  O6-methylguanine-DNA methyltransferase (MGMT) 
(ESTELLER et al., 2000; Kaina et al., 2007; Pan et al., 2012), which repairs guanine through the 
removal of the methyl adducts. Therefore, the majority of primary GBM submitted to 
standard therapy recurs and currently there is no accepted therapeutic approach to treat 
patients with secondary GBM (Sevim, Parkinson and McDonald, 2011). 
 
 
Figure 1.1 - Chemical structure of temozolomide, an alkylating agent used as the first-line 
treatment of GBM. 
 
b. Etoposide 
Etoposide (ETO, Figure 1.2) acts against Topoisomerase II enzyme, specifically targeting 
Topoisomerase IIa (Topo IIa) (Sevim et al., 2011). Topo IIa transiently cleaves both DNA 
strands to relax supercoiled DNA (Liu, 1989), facilitating DNA access to enzymes and 
allowing its replication or transcription. Therefore, ETO interferes with DNA metabolism, 
limiting cancer progression. 
The therapeutic potential of ETO has been tested in patients with recurrent malignant 
glioma but only 20% of the patients with GBM responded to this treatment (Fulton, Urtasun 
and Forsyth, 1996). 
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Figure 1.2 - Chemical structure of Etoposide, a DNA topoisomerase poison. 
 
c. Cisplatin 
Cisplatin or cis-diamminedichloroplatinum II (CDDP; Figure 1.3), a platinum anticancer drug, 
was approved by FDA in 1978, to treat testicular and bladder cancer (Galluzzi et al., 2012). 
Currently, it is also used as a first-line treatment for a broad range of solid tumors such as 
ovarian, cervical, head and neck, esophageal and lung (Rocha et al., 2014; Todd and Lippard, 
2010) and  as an adjuvant therapy in recurrent GBM (Brandes et al., 2004). CDDP has been 
used in combination with TMZ in patients with recurrent GBM (Brandes et al., 2004), due to 
the fact that CDDP reduces MGMT activity (Wang, L. and Setlow, 1989). Several other 
approaches have been used to treat GBM using CDDP in combination with other 
chemotherapeutics or other molecular agents (Kondo et al., 1995; Li, H. et al., 2012; Rocha 
et al., 2014).  
 
 
Figure 1.3 - Generation of mono- and bi-aquated cisplatin forms (aquation). 
 
CDDP is formed by one platinum ion surrounded by two chloride ions and two amine 
groups. Once in the intracellular environment, CDDP undergoes a process known as 
aquation, in which one or both of its chloride atoms are replaced by water (Figure 1.3). This 
phenomenon activates its action, since CDDP becomes positively charged and, consequently, 
capable of interacting with nuclear DNA and with other nucleophiles (Cullen et al., 2007; 
Rocha et al., 2014). Therefore, CDDP binds covalently to DNA, forming CDDP-DNA 
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adducts promoting a connection between two bases from the same DNA strand (intrastrand 
cross-links) or from opposite strands (interstrand cross-links) (Eastman, 1987). 
Consequently, the impairment of DNA structure results in cell-cycle arrest, through 
transcription and replication inhibition, which, in turn, triggers cell apoptosis (Todd and 
Lippard, 2010), or induces cell resistance to CDDP when drug lesions are recognized and 
removed by nucleotide excision repair (NER) (Martin, Hamilton and Schilder, 2008), present 
in the nuclear DNA (ncDNA).  
In addition to the mechanism of DNA damage repair, the increase of drug efflux, mediated 
by a member of ATP-binding cassette (ABC) transporters, particularly the multidrug 
resistance-associated protein 2 (MRP2, also known as cMOAT or ABCC2), limits the efficacy 
of CDDP during the course of the treatment (Szakács et al., 2006), leading to tumor relapse. 
In fact, MRP2 was found to be overexpressed in the plasma membrane of CDDP-resistant 
cells (Szakács et al., 2006). 
Mitochondrial DNA (mtDNA) emerges as a promising alternative cellular target for CDDP, 
since it is also sensitive to DNA intercalation agents (Li, W. et al., 2014) and lacks NER 
(Cullen et al., 2007). Moreover, once enclosed in mitochondria, CDDP would overcome 
cellular extrusion, since ABC efflux pumps only act on cytosolic substrates. Additionally, it 
was reported that mitochondria of cancer cells are more susceptible to injury than those of 
normal cells, which would enable to selectively target tumor tissues, through mitochondrial 
impairment (Fulda, Galluzzi and Kroemer, 2010). In fact, Wisnovsky and coworkers 
(Wisnovsky et al., 2013) demonstrated that the specific delivery of CDDP into mitochondria 
of ovarian tumor cells was sufficient to cause cell death and, importantly, the induced 
cytotoxicity affected both wild-type and CDDP-resistant ovarian cancer cells. 
Noteworthy, mitochondria are surrounded by a double-membrane that effectively protects 
the function of their machinery, restricting the access of a wide range of ions and molecules 
to their interior. Therefore, there is a need for designing vectors that can surpass this 
barrier, in order to aid drugs to enter into mitochondrial matrix, when this is the local they 
exert their activity, namely targeting mitochondrial DNA (Smith et al., 2012).  
 
Due to the advances in molecular biological research in the GBM field, cytotoxic agents have 
been used in combination with molecular approaches, which render cells more susceptible 
to drug toxicity. In this regard, gene therapy has emerged as a very promising 
alternative/complementary approach to chemotherapy, due to its potential for regulating 
gene expression. 
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Gene Therapy 
Gene therapy consists of the delivery of exogenous nucleic acid molecules into abnormal 
cells, in order to modulate genes that are aberrantly expressed as a consequence of a 
disease (Opalinska and Gewirtz, 2002). This therapy has potential to treat or impair the 
progression of several pathologies involving genetic deregulation, such as cancer, 
cardiovascular, infectious and neurodegenerative diseases (Opalinska and Gewirtz, 2002; 
Verma and Somia, 1997).  
Gene therapy includes three different strategies: gene insertion, gene replacement and gene 
silencing (Kay, 2011). The primary concept of gene therapy involves gene insertion, a 
strategy that attempts to induce the expression of a missing protein, through the delivery of 
a plasmid DNA (pDNA). Gene replacement takes advantage from technologies like zinc 
finger nucleases and DNA recombination, to repair a genetic mutation. Gene silencing 
approach benefits from RNA interference (RNAi) technology, which involves the usage of 
small interfering RNAs (siRNAs) or microRNAs (miRNAs), in order to interfere with a 
target messenger RNA (mRNA) that is typically overexpressed, owing to a genetic mutation 
(Hannon, 2002; Kay, 2011). 
 
a. Plasmid DNA (pDNA) 
Plasmid DNA is designed as a circular DNA molecule containing a therapeutic and/or a 
reporter gene under the control of a strong promoter, often that from cytomegalovirus 
(CMV). Therefore, through the use of plasmid DNA encoding a reporter gene, such as the 
green fluorescent protein (pGFP), information can be extracted about the percentage of cells 
that are efficiently transfected, by using a certain gene delivery system. Similarly, plasmid 
DNA can be delivered to mitochondria inside eukaryotic cells. A novel strategy to track GFP 
expression into the mammalian mitochondria has been described (Lyrawati, Trounson and 
Cram, 2011). Taking advantage of the fact that the translation system of mitochondria does 
not follow the “universal  genetic  code” (Anderson et al., 1981; Yoon, Koob and Yoo, 
2010), Lyrawati and co-workers (Lyrawati et al., 2011) designed a plasmid DNA encoding 
GFP (pmtGFP) that can only be translated by mitochondrial machinery.  
 
b. Small interfering RNAs (siRNAs) 
RNAi is a natural process of gene silencing, which was firstly observed in 1998, in the 
nematode Caenorhabditis elegans (Fire et al., 1998). After that, it was demonstrated that 
synthetic siRNAs of about 21 nucleotides in length were also effective in mediating 
sequence-specific gene silencing in a mammalian cell line (Elbashir et al., 2001). 
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SiRNAs are endogenously produced in mammalian cells (Figure 1.4). Cytoplasmic long 
double-stranded RNA (dsRNA) is processed by Dicer, which is an RNAse III enzyme, 
generating double-stranded siRNA. Then, siRNA duplexes bind to Argonaute 2 (AGO2) and 
are loaded into RNA-induced silencing complex (RISC), the sense (passenger) strand being 
discarded. After integration into RISC, the siRNA antisense (guide) strand pairs with a 
complementary sequence of the target mRNA, mRNA is cleaved by AGO2 and, 
consequently, mRNA translation is blocked (Fougerolles et al., 2007; Hannon and Rossi, 
2004; Kim and Rossi, 2007).  
Exogenous synthetic double-stranded siRNAs can be added to the cells, to promote 
suppression of specific genes. Once in the cytoplasm, these molecules are incorporated into 
the AGO2-RISC complex, circumventing the first steps of the endogenous dsRNA 
processing pathway, taking advantage of the cellular machinery to accomplish their task 
(Hannon and Rossi, 2004). 
 
Figure 1.4 - siRNA pathway in mammalian cells. Adapted from Fougerolles et al., 2007. 
 
After choosing the most adequate nucleic acid molecules for the desired gene therapy 
approach, the next step consists of the design of delivery systems able to reach the required 
intracellular target (cytosol, nucleus or mitochondria). 
 
c. Nucleic acid delivery systems 
Due to the inability of nucleic acids to circulate in the organism fluids without being 
degraded, and to surpass the membrane barriers so that they can reach the intracellular 
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target, there is a need to design nucleic acid delivery systems. These systems are divided into 
two categories: viral and non-viral. 
Retrovirus (Rv), adenovirus (Ad) and adeno-associated virus (AAV) are the most used viral-
vectors in the gene therapy field. In fact, viral vectors are the most effective gene carriers, 
although their potential is restricted by some aspects: Ad triggers immunogenic reactions; 
AAV presents a small size, which limits the genetic cargo capacity; and Rv, which integrates 
randomly the exogenous DNA into the host genome, can induce the expression of 
oncogenes by inserting upstream of these sequences and putting them under the control of 
the promoter contained in the exogenous plasmid DNA (Mountain, 2000). Consequently, 
non-viral vectors, characterized by their simplicity and safety features, have been developed 
as an alternative for viral vectors. In contrast with viral vectors, which take advantage of the 
innate ability of viruses for infection and release of nucleic acids into the infected cells, non-
viral vectors have to overcome several physiological and cellular barriers to introduce the 
genetic material into the target cells. Therefore, an efficient non-viral carrier should 
condense the nucleic acids, prevent their degradation by serum nucleases and confer them 
colloidal stability, so that nucleic acids circulate in blood stream before reaching the target 
cells. The next step involves the interaction of the delivery system with the cell surface, 
promoting its translocation into the cell. If complexes are taken up through endocytosis, 
gene carriers should promote destabilization of the endosomal membrane and nucleic acid 
escape, thus avoiding lysosomal degradation. In the case of siRNA delivery, complexes 
carrying these molecules must be disassembled in the cytoplasm, so that siRNA will become 
available to target mRNA.  The delivery systems carrying pDNA should also be able to  
promote its translocation across nuclear or mitochondrial membranes, in order to ensure 
gene expression (Simões et al., 2005).  
Cationic gemini surfactants (CGS) constitute an example of non-viral nucleic acid delivery 
systems, which interact with the nucleic acids through electrostatic and hydrophobic 
interactions and were shown to mediate efficient delivery of plasmid DNA (pDNA), both to 
the nucleus and to mitochondria (Bell et al., 2003; Cardoso et al., 2011, 2014, 2015a, 2015b; 
Fielden et al., 2001; Rosenzweig, Rakhmanova and Macdonald, 2001). Since CGS were used 
in the present work to deliver siRNA and pDNA, they will be described in more detail in the 
next sections. 
i. Cationic gemini surfactants: properties and structural 
features 
Gemini or dimeric surfactants are amphiphilic molecules containing two identical polar 
headgroups and two identical hydrophobic chains, connected by a rigid (e.g. stilbene) or 
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flexible (e.g. methylene) spacer, in contrast to the conventional surfactants, which have a 
single alkyl tail bound to a polar headgroup (Menger, Fredric and Keiper, 2000). Therefore, 
gemini surfactants are highly versatile molecules, being designed with different number of 
carbons in the alkyl chains and in the spacer, as well as with different polar headgroups, 
which can be nonionic (e.g. polyether sugar) or positively (e.g. ammonium) or negatively (e.g. 
phosphate, sulfate, carboxylate) charged. The spacer can vary in its nature, being polar (e.g. 
polyether) or nonpolar (e.g. aliphatic, aromatic), and rigid (e.g. stilbene) or flexible (e.g. 
methylene chain) (Menger, Fredric and Keiper, 2000; Weihs et al., 2005). 
Since the spacer and the tails have a hydrophobic character and the headgroups are 
hydrophilic, gemini surfactants can adopt different conformations when exposed to an 
air/water interface, depending on the electrostatic repulsion established between the two 
headgroups and the length and flexibility of the spacer. Thus, gemini surfactants assume an 
orientation in which they extend their tails above the water surface when the spacer is 
short, to minimize the electrostatic repulsions between the charged heads (Figure 1.5A), but 
acquire a conformation in which both tails are projected into the air if the spacer is long 
enough (Figure 1.5B); gemini surfactants may also assume a linear conformation, in which 
one of their hydrophobic tails is extended into the air and the other one is immersed into 
the water (Figure 1.5C). In contrast, monomeric surfactants assume only one orientation, in 
which they locate their headgroup at the air/water interface and extend their hydrophobic 
tail into the air (Figure 1.5D) (Karaborni et al., 1994; Menger, F and Littau, 1993). 
 
 
Figure 1.5 - Schematic representation of the possible orientations adopted by gemini 
surfactants (A-C) and monomeric surfactants (D) at an air/water interface. Adapted from 
Menger and Littau, 1993. 
 
Regarding micellization, it is remarkable that gemini surfactants have critical micellar 
concentrations (defined as the concentration above which the surfactant abruptly aggregates 
in water forming micelles; CMC) lower than monomeric surfactant analogs containing the 
same number of carbon atoms in the hydrophobic tail, being around two orders of 
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magnitude more efficient in forming micellar structures than their monomeric counterparts 
(Menger, F and Littau, 1993; Menger, Fredric and Keiper, 2000). On the other hand, while a 
monomeric surfactant forms spherical micelles in water, the analogue gemini surfactant can 
present a much richer phase diagram, forming spherical, worm-like or thread-like micelles, 
vesicles and/or other structures, depending on the concentration (Karaborni et al., 1994; 
Pérez et al., 2007). Taking into account that micellization is a highly cooperative process, 
driven by attractive hydrophobic interactions, which compensate the electrostatic repulsions 
established between surfactant ionic headgroups, it is not surprising that the CMC of gemini 
surfactants with short chains is higher than that of surfactants with long chains. Indeed, the 
increasing hydrophobicity of surfactants with long chains decreases their solubility, 
promoting gemini self-assembly, in order to reduce the hydrocarbon/water contact 
(Grosmaire et al., 2002; Menger, Fredric and Keiper, 2000). Less intuitive is the role played 
by the length and flexibility of the spacer in the surfactant aggregation behavior. In this 
regard, whereas gemini surfactants containing a rigid spacer avoid self-assembly into micelles, 
since the spacer inhibits the interaction between the alkyl tails, those having a short and 
flexible spacer, which allows to chain/chain association, are more prone to adopt a micellar 
structure (Menger, F and Littau, 1993). Interestingly, the molecular packing of gemini 
surfactants in micelles and monolayer is also dependent on the length of their spacer, short 
spacers inducing close packing, due to the hydrophobic forces established between the alkyl 
tails (Groth et al., 2004). Figure 1.6 illustrates schematically the packing displayed by 
aggregates of two gemini surfactants differing in the spacer length (12–2–12 and 12-4-12). 
 
 
Figure 1.6 - Schematic representation of two gemini surfactants differing in the spacer 
length. 12-2-12 reveals a more tight packing in a micelle and in a monolayer than 12-4-12 
surfactants. Adapted from Groth et al., 2004. 
 
Gemini surfactants also present a surface efficiency (as assessed by the quantity of surfactant 
required to decrease the surface tension by a given amount) three orders of magnitude 
higher than that displayed by the corresponding monomeric surfactants (Menger, F and 
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Littau, 1993). The superior surfactant properties exhibited by gemini surfactants as 
compared to those of monomeric counterparts (lower CMC values and higher surfactant 
efficiency) are allied to a higher efficiency in condensing nucleic acids, therefore requiring 
lower amounts of gemini surfactants than those necessary of the monomeric analogs to 
induce the same level of nucleic acid condensation (Karlsson, Eijk, van and Söderman, 2002). 
In fact, promising properties have been found in gemini surfactants, which, although known 
since 1971 (Robinson, 1971), were only rediscovered two decades ago, regarding their 
biomedical application as drug and gene delivery systems, as well as their usefulness for 
household products, cosmetic and food, among others (Kumar and Tyagi, 2014). The 
number of patents that cover this large range of gemini surfactant applications have strikingly 
increased in the last years. 
The possibility for structure modulation, including the high variety of molecules that can be 
linked to the spacer, has allowed the synthesis of a large range of different gemini surfactants 
with different structural features and, consequently, different physicochemical properties. In 
this regard, CGS of bis-quaternary ammonium salts (bis-quats) (Figure 1.7) have been the 
most extensively studied and characterized. This family of gemini surfactants is commonly 
designated by m-s-m (m and s for the number of carbon atoms in the hydrophobic chains 
and in the spacer group, respectively) and is represented by the general structure 
[CmH29(CH3)2N
+-(CH2)s-N
+(CH3)2CmH29]2Br−
 (Cardoso et al., 2011). As mentioned above, 
gemini surfactants reveal excellent properties for biomedical applications, although they 
present poor biocompatibility and biodegradability due to the absence of cleavable linkages 
in their structure (Pérez et al., 2007; Weihs et al., 2005). Natural surfactants have been used 
to overcome this problem, but their extraction and isolation involve high costs, are time-
consuming and inefficient (since small quantities of surfactants are recovered) (Silva et al., 
2009). Therefore, novel classes of surfactants have been synthesized, employing natural 
structural motifs, namely, amino acids, sugars and lipids. These classes of gemini surfactants 
combine the characteristic properties of the conventional gemini surfactants with an 
enhanced biocompatibility and biodegradability, inducing less cytotoxicity than the 
conventional bis-quats analogues (Brito et al., 2009; Silva et al., 2012; Singare and Mhatre, 
2012).  
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Figure 1.7 - Schematic representation of the general structure of cationic gemini 
surfactants of the alkanediyl-α,ω-bis(alkyldimethylammonium bromide) family.  
 
CGS derived from the amino acid arginine have been the most studied, revealing to be less 
toxic than the corresponding bis-quats, and to be readily biodegradable, while maintaining the 
outstanding self-assembling properties that are characteristic of gemini surfactants (Singare 
and Mhatre, 2012). Silva and coworkers synthesized cationic gemini surfactants based on 
serine (Figure 1.8) (Silva et al., 2012), following their observation that from three monomeric 
surfactants they synthesized, differing in the amino acid residue (tyrosine, serine and 4-
hydroxyproline) linked to the alkyl chain through an N-alkyl linkage, the one based on serine 
was that showing the best toxicological profile and the lowest cmc (Silva et al., 2009). This 
family of CGS is often referred to as (mSer)2Xs surfactants, where m and s are the number 
of carbon atoms in the alkyl tails and in the spacer group, respectively; Ser refers to the 
serine residue; the subscript 2 corresponds to the two chains and two polar headgroups that 
constitute a gemini surfactant and X refers to the type of chemical linkage between the 
amino acid and the spacer. 
 
 
Figure 1.8 - Schematic representation of the general structure of serine-derived gemini 
surfactants. 
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ii. Cationic gemini surfactant-based delivery systems: 
transfection efficiency 
CGS have been shown to promote efficient delivery of pDNA into the nucleus (Bell et al., 
2003; Fielden et al., 2001; Rosenzweig et al., 2001) and siRNA in the cytoplasm (Zheng et al., 
2014), in different types of cells. Moreover, recent studies performed in our laboratory have 
shown that gemini surfactants can mediate pDNA delivery into mitochondria (Cardoso et al., 
2015b). Remarkably, these amphiphilic molecules proved to mediate similar or higher levels 
of transfection than the commercial transfection reagent Lipofectamine 2000 (Bell et al., 
2003; Fielden et al., 2001; Rosenzweig et al., 2001), their efficiency revealing to be dependent 
on their structural features, the presence of helper lipids (described below) and the ratio 
between the positive charges of cationic gemini surfactants and the negative charges of 
nucleic acid phosphate groups. It was observed that gemini surfactant-nucleic acid binding 
strength is influenced by the spacer length, the most efficient complexation being achieved 
with gemini surfactants containing 2-3 carbon atoms-long spacer (Kirby et al., 2003), 
probably because it favors the best accommodation of nucleic acid phosphate groups for 
interacting with the positively charged headgroups of the gemini surfactants. The positive 
charges of gene carriers are needed not only to establish electrostatic interactions with the 
nucleic acids, promoting their condensation, but also to interact with the negatively charged 
membrane components at the cell surface, inducing cellular internalization of the nucleic acid 
delivery systems. 
Addition of CGS to nucleic acids results in the formation of complexes with different 
structures, depending on the nucleic acid employed (Figure 1.9), the complexation occurring 
due to the combination of electrostatic and hydrophobic interactions, the latter being 
established between surfactant apolar alkyl tails and the nucleic acid backbone (Fielden et al., 
2001). 
 
Figure 1.9 - Schematic representation of gemini/pDNA (A) and gemini/siRNA (B) 
complexation processes. Adapted from Wang, C. et al., 2007 and Falsini et al., 2014. 
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Endocytosis has been proposed as the preferred mechanism by which the gemini 
surfactant/DNA complexes are taken up by the cells. Thus, the complexes need to escape 
from endosomes, in order to prevent nucleic acid degradation in the lysosomal 
compartment. Bell and co-workers (Bell et al., 2003) suggested that gemini surfactant-based 
complexes adopt an inverted hexagonal phase (HII) in endosomal lumen, triggered by the low 
pH, which is characteristic of this organelle. The formation of this structure would 
contribute to destabilize the endosomal membrane (Figure 1.10), and, hence, to promote 
the escape from the endosome and the release of the nucleic acids into the cytoplasm, 
explaining the highly efficient transfection mediated by these surfactants. 
In fact, cationic gemini surfactants present an inverted cone molecular geometry due to the 
larger area of the headgroup cross-section as compared to that of the alkyl chains, being 
hence arranged in structures with positive curvature (micelles) in aqueous dispersions. 
Therefore, to adopt a fusogenic inverted hexagonal phase, these molecules must undergo a 
decrease of the headgroup cross-section area. In this regard, it was proposed that the 
decrease of pH during endosome maturation promotes a strong interaction between the 
doubly positive headgroup and the phosphate groups of the DNA, which results in charge 
neutralization and a further dehydration of both groups and, consequently, in a decrease of 
the headgroup cross-section (Bell et al., 2003; Kirby et al., 2003). 
 
 
Figure 1.10 - Proposed mechanism by which nucleic acids in gemini surfactant-based 
complexes escape from the endosome. Following cell internalization and once in the 
endosome, complexes undergo conformational changes, assuming a fusogenic inverted 
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hexagonal phase, which leads to endosomal membrane destabilization and, consequently, to 
nucleic acid release. If this conformational change does not occur, the complexes remain 
entrapped in the endosomal compartment as the endosomes mature into lysosomes, leading 
to nucleic acid degradation. A shows the endocytosis of the complex by cell membrane 
invagination and B depicts the formation of the inverted hexagonal phase in the endosome. 
Adapted from Bell et al., 2003. 
 
Nevertheless, Rosenzweig and collaborators (Rosenzweig et al., 2001) observed that 
transfection activity mediated by gemini surfactants is reduced or even abolished in the 
presence of serum. It was hypothesized that the addition of colipids (also known as helper 
lipids) to gemini surfactants could overcome this inhibitory effect of serum, allowing their 
widespread application, namely in vivo. Since then, several studies have revealed that the 
addition of helper lipids to the gemini surfactant/nucleic acid complexes can further increase 
their biological activity (Cardoso et al., 2014, 2015a; Grosmaire et al., 2002; Wang, C. et al., 
2007) 
 
iii. Role of helper lipids in transfection activity 
Cationic liposomes, the most extensively used non-viral vectors, are usually mixed with 
“helper lipids”, in order to enhance gene delivery. Unsaturated phosphatidylethanolamines 
(PE), such as dioleoylphosphatidylethanolamine (DOPE), have been the most widely 
employed helper lipids (Hui et al., 1996) and shown to improve  the ability of cationic 
liposomes to transfect a large number of cells in vitro. This fact has been attributed to the 
propensity of DOPE to undergo a transition from a bilayer to a hexagonal phase under acidic 
pH (Hafez and Cullis, 2001; Koltover, Salditt and Ra, 1998), which may facilitate fusion with 
or destabilization of target membranes, namely the endosomal membrane (Koltover et al., 
1998; Siegel and Epand, 1997; Zuhorn et al., 2005), following cell internalization of cationic 
liposome-based complexes through endocytosis. The hexagonal phase formation can also 
contribute to the destabilization of the complexes (Bell et al., 2003), leading to the 
dissociation of the nucleic acids from their carrier (Zuhorn et al., 2005). These two events 
contribute to the escape of nucleic acids from the endosomal compartment, which allow 
them to gain access to the cytoplasm, being ready to perform their task (in the case of 
siRNA) or to cross the nuclear or mitochondrial membranes (in the case of pDNA). 
Cholesterol is another helper lipid commonly employed, particularly in in vivo studies, in 
order to enhance transfection mediated by cationic vectors. When added to a bilayer, 
cholesterol increases the lipid packing and reduces the free volume, inducing a liquid-
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ordered (Lo) phase at high concentrations (Almeida, Vaz and Thompson, 1992), and 
conferring high stability to the lipid/surfactant arrangements. Consequently, cholesterol-
enriched complexes, due to their remarkable stability, exhibit a high circulation lifetime, 
likely owing to their poor interaction with serum proteins (Crook et al., 1998; Maslov and 
Zenkova, 2011; Semple, Chonn and Cullis, 1996). 
 
In the present work, the potential of gemini surfactants to be used as pDNA and siRNA 
delivery systems will be fully explored, taking advantage of the high versatility of these 
molecules and their combination with helper lipids. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 2 
 
 Objectives 
 
 
 
28 
 
Objectives 
 
. Evaluation of the efficiency of cationic gemini surfactants from conventional and serine-
derived bis-quat families to deliver siRNAs into human U87 GBM cells. 
 
. Employment of a combined approach involving i. survivin downregulation mediated by 
siRNAs formulated in a cationic gemini surfactant-based delivery system and ii. 
administration of the chemotherapeutic agents temozolomide and etoposide, aiming at 
obtaining a synergistic cytotoxic effect in GBM cells. 
 
. Assessment of the ability of serine-derived bis-quats to promote nuclear and mitochondrial 
delivery of plasmid DNA in the human recurrent DBTRG-05MG GBM cells towards 
successful gene expression. 
 
. Development of a gemini surfactant-based system capable of co-delivering pDNA and 
CDDP to nucleus and mitochondria in order to enhance drug therapeutic efficacy in GBM. 
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Materials and methods 
3.1. Materials 
Gemini surfactants were synthesized, purified and physically characterized in Centro de 
Investigação em Química, Department of Chemistry and Biochemistry, University of Porto 
(Porto, Portugal) and kindly provided for our studies thanks to a collaboration with Prof. 
Eduardo Marques and Prof. Luísa do Vale from that Institution.  
The lipids 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE) and cholesterol (Chol) 
were purchased from Avanti Polar Lipids (Alabaster, AL). 
Lipofectamine RNAiMAX was acquired from Invitrogen (Carlsbad, CA). The siRNA duplex 
against GFP (siGFP) (sense: 5′-GCAAGCUGACCCUGAAGUUCdTdT-3′) and the non-
targeting siRNA duplex used as control (siMUT) (sense: 5′-
UUCUCCGAACGUGUCACGUdTdT-3′) were synthesized by GeneCust (Dudelange, 
Luxembourg). The DY547-labeled non-targeting siRNA duplex (sense: 5′-
UAAGGCUAUGAAGAGAUACdTdT-3′) and the anti-survivin siRNA duplex (sense: 5′-
GGACCACCGCAUCUCUACAdTdT-3′) were purchased from Dharmacon (Lafayette, CO, 
USA). Plasmid DNA (pDNA) encoding nuclear GFP (pEGFP-C1, herein designated pncGFP) 
was obtained from Clontech (CA, USA) and plasmid DNA encoding mitochondrial GFP 
(pmtGFP) was synthesized and kindly provided by Prof. Diana Lyrawati, Brawijaya University 
(East Java, Indonesia). Custom-designed primers for survivin and for the control HPRT-1 
were acquired from Qiagen. 
Temozolomide and etoposide were acquired from Selleckchem (Munich, Germany) and 
cisplatin was purchased from Sigma (Germany) as well as DMSO, which was used to prepare 
drug stock solutions. 
The anti-survivin antibody (goat) was purchased from Santa Cruz (Santa Cruz Biotechnology, 
Inc., Heidelberg, Germany), the anti-β-actin antibody (mouse) and the secondary antibodies 
were acquired from Sigma (St. Louis, MO, USA). 
 
3.2. Methods 
Gemini surfactant-based complexes 
i. Preparation of binary (gemini/nucleic acids) and ternary 
(gemini/nucleic acids/helper lipids) gemini surfactant-based 
complexes 
Gemini surfactant-based complexes were prepared as previously described (Cardoso et al., 
2014). Briefly, an aqueous solution of gemini surfactant was prepared at a concentration of 
31 
 
0.5 mM and filtered through 0.22 μm pore-diameter filters (Schleicher & Schuell, BioScience, 
Germany). Binary complexes were prepared by mixing an aliquot of gemini solution in HBS 
with a constant amount of siRNA (siGFP or siSURV, to promote GFP or survivin silencing, 
respectively, or siMUT) or pDNA (pncGFP or pmtGFP, to promote nuclear or 
mitochondrial GFP expression), in order to obtain the desired surfactant/nucleic acid (+/-) 
charge ratios, followed by incubation at room temperature for 30 min. To produce ternary 
complexes, a suspension of MLVs composed of DOPE:Chol (2:1 molar ratio) was previously 
prepared by mixing, at this molar ratio, the helper lipids (HL) DOPE and Chol dissolved in 
chloroform. The lipid mixture was dried under vacuum in a rotatory evaporator, and the 
lipid film was hydrated with HBS (pH 11.0) to a final lipid concentration of 0.5 mM. The 
resulting multilamellar vesicles (MLV) were then sonicated for 3 min, in a sonication bath, 
and added to surfactant/nucleic acid complexes previously incubated for 15 min at room 
temperature, in order to obtain the desired surfactant/helper lipid molar ratios, followed by 
a further 15 min incubation. Figure 3.1 schematizes the method of complex preparation. 
 
 
Figure 3.1 – Schematic representation of the methods used for the preparation of binary 
and ternary complexes based on gemini surfactants. Binary complexes were prepared by 
mixing an aqueous solution of gemini surfactant with HBS and siRNA or pDNA, to obtain 
the desired surfactant/nucleic acid (+/-) charge ratios. After 30 min of incubation, at room 
temperature, complexes were added to plated U87 cells. To produce ternary complexes, a 
volume of a suspension of MLVs composed of DOPE:Chol (2:1 molar ratio) was added to 
surfactant/nucleic acid complexes, after 15 min of incubation, at room temperature, to 
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obtain the desired surfactant/lipid molar ratios. After a further period of 15 min of 
incubation, these complexes were added to the plated U87 cells. 
 
ii. Preparation of gemini surfactant-based complexes containing 
cisplatin 
For the preparation of gemini/pDNA/cisplatin complexes, a constant amount of plasmid 
DNA was mixed with a solution of CDDP in HBS at different concentrations (4, 8 and 16 
µM). The mixture was left incubating for 10 min to promote association of the plasmid DNA 
with CDDP and then added to the gemini surfactant, to obtain the 8/1 surfactant/pDNA (+/-) 
charge ratio. After an incubation period of 30 min, at room temperature, complexes were 
added to the cells. 
 
Physico-chemical characterization of the complexes  
i. Size measurement  
The hydrodynamic size distribution of the ternary complexes of surfactant, siRNA and 
helper lipids was evaluated by dynamic light scattering (DLS), also called photon correlation 
spectroscopy (PCS) and quasi-elastic light scattering (QELS). 
The central concept in DLS, as a technique for determining the size of particles in 
suspension, is that the scattered light intensity from diffusing particles, whose relative 
positions undergo Gaussian random changes (i.e. display Brownian motion), fluctuates in 
time, giving information regarding particle diffusion coefficient, which correlates with particle 
size. In fact, the hydrodynamic diameter can be determined from the diffusion coefficient 
using the Stokes-Einstein relationship expressed in the equation: 
 
Dh = kBT / 3πηDt 
 
where Dh is the hydrodynamic diameter, Dt is the translational diffusion coefficient (obtained 
by DLS), kB is the Boltzmann’s constant, T is the absolute temperature and η is the viscosity 
of the medium (Cardoso et al., 2009). 
Immediately before analysis, the complexes were prepared as previously described and 
diluted in HBS. The assay was performed using a Submicron Particle Size Analyzer, Beckman 
Coulter N4 Plus, at 25 ºC. The detection angle was fixed at 90° and Dh calculations were 
automatically performed by the instrument’s software. 
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ii. Zeta potential determination  
In the field of nanotechnology, the interactions established between nanoparticles play an 
important role in the properties they assume in suspension. If the particles display highly 
positive or negative charge, electrostatic repulsive forces are generated, which keep each 
particle discrete and disperse in suspension; on the other hand, particles electrically neutral 
tend to agglomerate. 
An electrical double layer, composed of a Stern layer (inner region) and a diffuse layer (outer 
region), is formed around each particle (Figure 3.2). The point where these two layers meet 
forms a boundary, called slip plane. In the presence of an electric field, a charged particle 
moves with a fixed velocity (electrophoretic mobility).  This mobility is related to the Zeta 
potential, which can be determined using a combination of electrophoresis and Laser 
Doppler Velocimetry, and corresponds to the electrical potential at the slip plane boundary. 
The calculation of the zeta potential takes into account the viscosity and the dielectric 
constant of the medium (Zeta Sizer Nano Series User Manual, Ch. 1.). 
Zeta potential measurement of the (14Ser)2N5/siGFP/HL complexes was performed in the 
aqueous buffer HBS, at 25 °C, using a Zetasizer Nano ZS, ZN 3500, with a 532 nm laser 
(Malvern Instruments, UK). The complexes were prepared immediately before analysis, 
placed in the measuring cell and an electric current of 3.0 mA was applied. Measurements 
were recorded and the zeta potential was calculated for each scattering angle (8.6º, 17.1º, 
25.6º, and 34.2º). 
 
 
Figure 3.2 - Schematic representation of the distribution of positive and negative ions 
around a highly negative particle in an aqueous solution. The Stern layer is firmly attached to 
the particle and is formed by positive ions electrostatically attracted by the particle. Diffuse 
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layer is composed of loosely attached positive ions, which results from a dynamic equilibrium 
between attraction by the particle and repulsion by the Stern layer. The ion concentration of 
positive ions gradually decreases with distance, until the equilibrium with the solution is 
reached. Modified from Zeta Sizer Nano Series User Manual, Ch. 1. 
 
iii. PicoGreen intercalation assay 
PicoGreen intercalation assay was used in this work to evaluate the degree of siRNA 
protection conferred by gemini surfactant-based delivery systems. PicoGreen is a fluorescent 
intercalating probe whose fluorescence is enhanced upon binding to nucleic acids, 
fluorescence intensity reflecting, hence, the amount of accessible/free nucleic acid present in 
the sample. Therefore, this simple, rapid, and sensitive technique allows to estimate the 
efficiency of gene carriers in protecting nucleic acids, for example from the access of 
nucleases. 
Complexes containing 14 pmol of siRNA were prepared in a total volume of 100 µL of HBS. 
After 30 min of incubation, at room temperature, complexes were transferred to a 96-well 
blackwalled plate (Corning, NY, USA) and 100 µL of PicoGreen (Molecular Probes, Eugene, 
OR), diluted according to the manufacturer's instructions (1:200 dilution in HBS buffer), 
were added to each well. Following an incubation period of 5 min, at room temperature, 
PicoGreen fluorescence was measured using a SPECTRAmax Gemini EM fluorimeter 
(Molecular Devices, Union City, CA). The excitation and emission wavelengths were set at 
485 and 520 nm, respectively. The fluorescence intensity was measured immediately after 
complex preparation at 25 and 37 °C, and every 10 min for the period of 1 h, at 37 °C. The 
amount of siRNA available to interact with the probe was calculated by subtracting the 
values of residual fluorescence (PicoGreen in the absence of siRNA) from those obtained for 
each measurement, and expressed as a percentage of the maximum fluorescence obtained 
with naked siRNA, according to the Equation: 
 
% of free siRNA = [(F-F0)/(F100-F0)]x100 
 
where F is the fluorescence intensity measured after adding the PicoGreen solution to the 
complexes, F100 (corresponding to 100% of free siRNA) represents the maximum 
fluorescence intensity obtained using naked siRNA in the same amount as that associated 
with the complexes, F0 (corresponding to 0% of free siRNA) is the residual fluorescence 
intensity, obtained in the absence of siRNA, which represents the maximum protection of 
the nucleic acid. 
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Cells culture, transfection and pharmacological treatments 
i. Cell lines and culturing conditions  
U87 human glioblastoma cell line was kindly donated by Dr Peter Canoll (Columbia 
University, New York, NY). A modified U87 cell line constitutively overexpressing GFP 
(U87-GFP) was derived from U87 cells, through infection with a lentiviral vector, as 
previously described (Costa et al., 2013). The human recurrent glioblastoma cell line 
DBTRG-05MG, kindly provided by Dr. Massimiliano Salerno (Siena Biotech, Italy), was 
established from a glioblastoma patient treated with local brain irradiation and multidrug 
chemotherapy. All GBM cell lines were maintained in culture at 37º C, under a humidified 
atmosphere containing 5% CO2. U87 and U87-GFP cells were grown in Dulbecco modified 
Eagle’s medium – high glucose (DMEM–HG; Sigma, D5648) and DBTRG-05MG cells were 
grown in Roswell Park Memorial Institute 1640 (RPMI, Sigma, R4130) medium. Both media 
were supplemented with 10% (v/v) heat-inactivated fetal bovine serum (FBS; Sigma, St. Louis, 
MO, USA), 100 units/mL penicillin (Sigma) and 100 µg/mL streptomycin (Sigma). 
U87, U87-GFP and DBTRG-05MG cells grown in monolayer were detached using enzyme-
free cell dissociation buffer at 50–70% confluence. Cell suspensions were diluted 1:1 with 
trypan blue and cells were counted with a hemocytometer. For flow cytometry, qRT-PCR 
and Western blot analyzes, U87 and DBTRG-05MG cells were plated at a density of 7x104 
and 6x104 cells/well, respectively, in 1 mL of complete medium supplemented with FBS (10% 
v/v), in 12-well cell culture plates. For the assays involving the use of chemotherapeutical 
drugs (temozolamide, etoposide and cisplatin) U87 and DBTRG-05MG cells were seeded at 
a density of 6x103 and 5x103 cells/well, respectively, in 100 µL of complete medium,  onto 96-
well plates, and the border wells were filled with 200 µL sterile water. 
 
ii. Cell transfection 
Twenty-four hours after plating, cell medium was replaced with fresh medium (serum-free 
OptiMEM medium or DMEM medium containing 10, 20, 30 or 60% of serum for U87 and 
U87-GFP cells). 
Gemini surfactant-based complexes, prepared at different (+/-) charge ratios and containing 
siRNAs against the selected target mRNA or pDNA encoding GFP, were added to the cells 
at a final concentration of 50 nM for siRNA and 1 µg/mL for pDNA. A non-targeting siRNA 
sequence (siMUT) was also employed to discriminate target-gene silencing from non-specific 
effects. 
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Lipofectamine RNAiMAX (Invitrogen, Carlsbad, CA), prepared according to manufacturer’s 
instructions, was used as a positive control for the delivery of the siRNA against survivin. 
Following 4 h incubation (in 5% CO2, at 37 °C), the medium was replaced with fresh medium 
containing FBS (10% v/v) and antibiotics. 
 
iii. Confocal microscopy studies 
Confocal microscopy was used to evaluate the ability of gemini surfactants to mediate an 
efficient delivery of siRNAs into the cells, in the presence and absence of serum. 
Twenty-four hours before transfection, U87 cells (2x104 cells/well) were plated onto 8-well 
chambered coverslips (Ibidi, Munich, Germany). After this period, the medium was replaced 
by fresh serum-free medium (0%) or medium containing 10% of serum and the complexes 
formulated with D540-labelled siRNAs (50 nM) were added to the cells. 
After a further 4 h incubation, cells were rinsed twice with PBS and incubated with the DNA 
binding dye Hoechst 33342 (1 μg/mL, Molecular Probes, Eugene, OR) for 5 min (protected 
from light). Cells were washed twice with PBS and the fluorescence distribution was 
visualized using a Zeiss Axiovert confocal scanning microscope (Zeiss, Jena, Germany), under 
the 60⨯ oil immersion objective. 
 
iv. Cell incubation with the drugs  
In order to determine if survivin silencing sensitized U87 cells to chemotherapeutic agents, 
24 h post transfection, the medium was replaced by fresh medium and the drugs 
temozolomide (400 μM) and etoposide (1.5 μM), prepared in DMEM, were added to the 
cells. Forty-eight hours after incubation of non-transfected and transfected cells with the 
drugs, cell viability was evaluated using the Alamar blue assay. 
 
In order to assess the sensitivity of DBTRG-05M cells to the anti-cancar drug cisplatin, 24 h 
after plating, RPMI medium was replaced with OptiMEM, and CDDP, prepared in HBS, was 
added to 96-well plates to yield the final concentrations of 2, 4, 8, 16, 31, 62, 125, 250, 500, 
1000 μM. After 4 h of incubation, CDDP-containing medium was replaced with fresh RPMI 
medium. 
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Evaluation of molecular outcomes of cell transfection 
i. Gene silencing and expression evaluated by flow cytometry 
Flow cytometry simultaneously measures and analyzes multiple physical characteristics of 
cells such as relative particle size, relative granularity or internal complexity, and relative 
fluorescence intensity, as cells pass one at a time through a focused laser beam. 
This technique was used to measure the relative fluorescence intensity of the cells after 
transfection with the different complexes. U87 cells constitutively expressing GFP (U87-
GFP) were employed to examine the level of GFP knockdown achieved with siGFP- and 
siMUT-containing complexes. The efficiency of the transfection mediated by gemini-based 
formulations carrying pncGFP or pmtGFP was evaluated in DBTRG-05MG cells, by 
calculating the percentage of cells expressing GFP. 
Forty-eight hours after transfection, cells were detached using enzyme-free cell dissociation 
buffer (5 min, at room temperature). Cells were, then, washed by centrifugation (200 g, 4 
ºC, 5 min) in 950 µL of ice-cold PBS and the resulting pellets were resuspended in 200 µL of 
ice-cold PBS. The cell suspensions were immediately analyzed by flow cytometry using a 
FACS-Calibur flow cytometer (BD Biosciences, San Jose, CA). To discriminate viable and 
dead cells and to exclude doublets, cells were appropriately gated by forward/side scattering 
from a total of 10,000 events. Data were stored and analyzed using CellQuest software. The 
mean fluorescence was normalized with the fluorescence intensity of non-transfected cells. 
 
ii. Quantification of survivin mRNA levels by qRT-PCR 
Quantitative real time PCR (qRT-PCR) is a useful tool to quantify the alterations of the 
levels of mRNA for a given target protein upon cell transfection with siRNA or pDNA. Real 
time PCR consists of the amplification of a specific complementary DNA (cDNA) sequence 
(complementary to the mRNA of interest), using specific primers. Consecutive cycles of 
denaturation, primer annealing and elongation, allow for the amplification of the sequence to 
which the primers are complementary. The PCR mixture contains a fluorophore molecule 
which intercalates the nucleic acids and fluoresces only in this environment. The real time 
PCR system, acting as a fluorimeter, detects the increase of fluorescence, which is 
proportional to the amount of copies of the sequence being amplified, thus providing 
quantitative data, with no need for further quantification of the target sequence (Freeman, 
Walker and Vrana, 1999). 
RNA was extracted from the whole-U87 cells (24 and 48 h after cell transfection with 
complexes containing the target siSURV or the non-target siMUT), using the NucleoSpin 
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RNA Isolation Kit (Macherey-Nagel, Düren, Germany), according to manufacturer’s 
recommendations. 
In order to lyse the cells, the Buffer RA1 was mixed with ß-mercaptoethanol (100:1) and the 
resulting solution was added to the plated cells, followed by a manual disruption. The lysates 
were filtered through NucleoSpin Filters and centrifuged at 11,000 g, for 1 min at room 
temperature, to reduce viscosity. Then, 350 µL ethanol (70%) were added to the 
homogenized lysates, mixed by pipetting up and down (8 times) and loaded into a 
NucleoSpin RNA Column, followed by centrifugation at 11,000 g, for 30 s. The silica 
membrane of NucleoSpin RNA Columns were desalted with 350 µL of Membrane Desalting 
Buffer and centrifuged at 11,000 g, for 1 min. In order to digest any contaminating DNA 
present in the samples, 95 µL of rDNase reaction mixture were applied directly onto the 
center of the silica membrane of the column, followed by incubation for 15 min at room 
temperature. The silica membrane was then washed and dried by centrifugation twice with 
buffer RAW2 and once with buffer RA3. RNA was eluted in 30 µL RNase-free water.  
Since the complete elimination of genomic DNA from RNA preparations cannot be 
guaranteed, it is important to include a No Reverse Transcription control (NRT) in the 
reverse transcription reaction. This control contains all the components of the cDNA 
synthesis assay except for the reverse transcriptase. Any qRT-PCR amplification signal 
obtained in this condition corresponds to genomic DNA unspecific products. 
After RNA quantification, 300 ng of RNA (extracted from U87 cells 24  or  48 h after cell 
transfection) were converted to cDNA using the NZY First-Strand cDNA Synthesis Kit 
(NZYTech, Lisbon, Portugal), by applying the following protocol: 30 min at 50 ºC (cDNA 
synthesis) followed by 5 min at 85 °C (heat-inactivation of the reverse transcriptase). After 
transcription, the samples were further incubated for 20 min at 37 ºC with 0.5 µL of RNase 
H (from E. coli), to specifically degrade the RNA strand in RNA-cDNA hybrids.  
The resulting cDNA was further diluted 10 times with RNase-free water prior to 
quantification by qRT-PCR. 
Quantitative PCR was performed in a StepOnePlus Real-Time PCR System (Applied 
Biosystems, USA) using 96-well microtiter plates and the iQ SYBR Green Supermix Kit (Bio-
Rad).  
Primers for the target gene (survivin) and housekeeping gene (hypoxanthine 
phosphoribosyltransferase 1; HPRT1) were custom-designed and acquired from Invitrogen. 
A master mix was prepared for each primer set, containing a fixed volume of SYBR Green 
Supermix and the appropriate amount of each primer, to yield a final concentration of 150 
nM. For each reaction, performed in duplicate, 6 µL of master mix were added to 4 µL of 
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cDNA template. In order to detect contaminants that could be present in the reaction 
components and also to determine dimmer formation between the primers, a No Template 
Control (NTC) was performed for the target and reference genes, where the cDNA 
template was replaced by RNase free-water. The NRT control was also performed for both 
target and reference genes, to detect possible DNA contaminants that could be present in 
the sample. 
The reaction conditions consisted of enzyme activation and well-factor determination for 1 
min and 30 s at 95 ºC, followed by 45 cycles for 10 s at 95 ºC (denaturation), 30 s at 55 ºC 
(annealing), and 30 s at 65 ºC (elongation). The melting curve protocol started immediately 
after amplification and consisted of 1 min heating at 55ºC followed by 80 steps of 10 s, with 
an increase of 0.5 ºC in temperature at each step. Threshold values for threshold cycle (Ct) 
determination were generated automatically by the StepOne Software. 
To determine the mRNA fold change, survivin gene expression was compared to the 
endogenous reference gene (HPRT1 gene), taking into consideration the different 
amplification efficiencies of both genes in all experiments, according to the Pfaffl method 
(Pfaffl, 2001): 
Δ Ct (survivin) = Ct (control) – Ct (sample) 
Δ Ct (HPRT1) = Ct (control) – Ct (sample)  
 
mRNA fold change = (Esurvivin)Δ
CP(survivin)
 /(EHPRT1)Δ
CP(HPRT1) 
 
where Δ Ct (survivin) and Δ Ct (HPRT1) represent the Ct deviation of control – sample of the 
survivin and HPRT1 transcripts, respectively; and Esurvivin and EHPRT1 are the real-time PCR 
efficiency of survivin and HPRT1 transcripts, respectively, which are determined according to 
the equation  
E = 10-1/S-1 
 
where S is the slope of the standard curve of serial sample dilutions. 
 
iii. Quantification of survivin levels by Western blot 
To confirm that the decrease of survivin mRNA levels, analyzed by qRT-PCR, resulted in a 
reduction of the survivin protein expression, Western blot analysis was also performed. 
Western blot consists of an electrophoretic separation of proteins, based on their molecular 
weight, followed by an electrotransference of the separated proteins from the 
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electrophoresis gel to an appropriate membrane for antibody labeling, and protein 
quantification (Mahmood and Yang, 2012).   
Forty-eight hours after U87 cell transfection with siRNA-containing complexes, protein was 
extracted, at 4 ºC, from 12-well microplates using RIPA lysis buffer (50 mM Tris pH 8.0, 150 
mM NaCl, 50 mM EDTA, 0.5% sodium deoxycholate, 1% Triton X-100) containing a 
protease inhibitor cocktail (Sigma), 10 μg/mL DTT and 1 mM PMSF. The protein content of 
the lysates was quantified using the Bio-Rad protein assay (Bio-Rad) and 30 μg of total 
protein were resuspended in a loading buffer (20% glycerol, 10% SDS, 0.1% bromophenol 
blue), denaturated upon 5 min incubation at 95 ºC and loaded onto a 12% polyacrylamide gel 
for electrophoretic separation. 
After electrophoresis, the proteins were blotted onto a PVDF membrane according to 
standard protocols. After 1 h of membrane blocking in 5% nonfat milk, the membrane was 
incubated with the primary antibody (anti-survivin 1:200, Santa Cruz Biotechnology, Inc., 
Heidelberg, Germany) overnight, at 4ºC. Following this time period, the membrane was 
washed three times with TBS/T (25 mM Tris-HCl, 150 mM NaCl, 0.1% Tween) and 
incubated with the appropriate secondary antibody (1:10000) for 2 h, at room temperature. 
Then, the membrane was washed three times with TBS/T and incubated with the enzyme 
substrate ECF (alkaline phosphatase substrate; 20 μL of ECF/cm2 of membrane) for a 
maximum of 5 min, at room temperature. Fluorescence detection was achieved at 570 nm 
using a ChemiDocTM Touch Imaging System (Bio-Rad). Equal protein loading was shown by 
reprobing the membrane with an anti-β actin antibody (1:1000, Sigma) and with the 
appropriate secondary antibody. Prior to membrane reprobing, the blots were washed in 
40% methanol for 30 min, followed by a fast wash with Milli-Q water. The membrane was 
then washed with a glycine solution (0.1M, pH 2.5) for 40 min, further washed three times 
with TBS/T and blocked for 1 h in 5% nonfat milk. 
The analysis of band intensity was performed using ImageJ Software (Wayne Rasband 
National Institutes of Health, USA), and the survivin band intensity was normalized to β-actin 
in each experiment, in order to correct variations in the total protein content.  
 
Evaluation of cellular outcomes of cell treatment 
i. Evaluation of cell viability 
The evaluation of the efficacy of gemini-based formulations to mediate gene silencing or 
expression was accompanied by cytotoxicity assessment, since the toxic effects exerted by 
the delivery systems on cells can constitute a limitation for their application in in vitro and in 
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vivo studies. Cell viability was also assessed in order to evaluate the outcome of cell 
treatments (therapeutic gene silencing or drug administration). 
Cell viability was assessed by a modified Alamar blue assay, as previously described (Konopka 
et al., 1996). Resazurin (blue) is the active ingredient of the Alamar blue assay, which is 
reduced by metabolically active cells to resorufin (pink), this technique allowing, hence, to 
distinguish metabolically active from metabolically inactive cells. This technique is simple, 
cheap and easy to perform. Moreover, the colorimetric assay can be performed without cell 
lysis, since resazurin is a cell permeable dye, and without the detachment of adherent cells, 
which makes possible the use of the cells for additional assays.  
An appropriate volume of resazurin dye (10% v/v) in DMEM–HG medium (for U87 cells) or 
in RPMI medium (for DBTRG-05MG cells) was added to each well.  After color development 
(upon 45 min to 1 h and 2 h to 3 h of incubation at 37 °C, for 12- and 96-well plated cells, 
respectively), 150 µL of supernatant were collected from each well, transferred to clear 96-
well plates, and the absorbance was measured in a SPECTRAmax PLUS 384 
spectrophotometer (Molecular Devices, Union City, CA), at 570 and 600 nm. Cell viability (as 
a percentage of control cells) was calculated according to the equation: 
 
Cell viability (% of control) = [(A570 – A600)/(A'570 –  A'600)] x100 
 
where A570 and A600 are the absorbances of the treated cells, and A’570  and A’600 are 
those of the control (non-treated cells), at the indicated wavelengths. 
 
ii. Evaluation of cell proliferation 
The sulforhodamine B (SRB) assay was conducted to assess the effects of cisplatin, free or 
included in a surfactant/DNA complex, on the proliferation of DBTRG-05MG cells. This 
assay is based on the ability of the anionic dye SRB to bind to basic amino acid residues of 
proteins, forming an electrostatic complex, under moderately acid conditions. Therefore, the 
amount of bound dye is proportional to the amount of protein and, consequently, to the 
number of cells, being an indicator of cell proliferation. The color development is rapid and 
stable and SRB assay only requires simple equipment and inexpensive reagents, being also 
highly efficient and allowing to test a large number of samples in a short period of time. 
Sulforhodamine B assays was performed as previously described (Vichai and Kirtikara, 2006). 
Briefly, immediately after treatment with cisplatin and 24, 48, 72 and 96 h after treatment, 
cells were fixed by adding 100 µL of a solution of acetic acid at 1% in methanol to each well, 
followed by 1 h incubation at -20 ºC. Cells were then rinsed and left to dry at 37 ºC, for 20 
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min, before being incubated with 200 µL of 0.05% SRB staining solution containing 1% acetic 
acid, for 1 h at 37 ºC. To remove the unbound dye, cells were washed several times with a 
1% solution of acetic acid in Milli-Q water and, then, left to dry at 37 ºC, for 20 min. The 
protein-bound dye was solubilized in 10 mM Tris buffer (pH 10) for 15 min, under gentle 
agitation, and the absorbance was measured at 540 nm in a microplate reader 
(SPECTRAmax PLUS 384, Molecular Devices, Union City, CA). 
 
iii. Cell cycle analysis 
In order to evaluate the cytostatic effects of cisplatin on DBTRG-05MG cells, the 
distribution of the cell population along the different phases of the cell cycle was analyzed by 
quantification of the DNA of each cell. To accomplish that, propidium iodide, which 
intercalates into the double stranded macromolecule, was used to fluorescently label the 
nucleus of the cell. Quiescent and G1 cells have one copy of DNA, whereas cells in G2/M 
phase of the cell cycle have two copies of DNA. Therefore, when cells in G2/M replication 
phases passed through the focused laser beam, the fluorescence intensity detected was twice 
that of quiescent or G1 cells. Cells in S phase are synthesizing DNA, thus revealing 
fluorescence values between those of quiescent or G1 cells and G2/M cells (Figure 3.3).  
 
 
Figure 3.3 - Cell cycle. Cells in G1/G0 phase are diploid (2N) and cells in G2/M phase are 
tetraploid (4N). DNA content in S phase varies between 2N and 4N. Adapted from 
https://www.miltenyibiotec.com/~/media/Files/Support/Macs-Technology/AP_MACSQuantApp_CellCycle.ashx. 
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Twenty-four hours after cells were seeded in 12-well plates, the medium was replaced with 
a serum free medium and cells were transfected with (18Ser)2N5/pDNA or 
(18Ser)2N5/pDNA/CDDP complexes (at 8 µM CDDP) or treated with free CDDP, at the 
same concentrations. After 4 h of incubation, the medium was replaced by complete RPMI 
medium and, forty-eight hours later, cells were detached using enzyme-free cell dissociation 
buffer (10 min, at room temperature) and washed by centrifugation (300 g, 4 ºC, 5 min) with 
ice-cold PBS. The supernatant was discarded and cells were fixed by slowly adding 200 μL of 
70% ethanol, while vortexing the mixture at low speed. After 24 h incubation at 4 ºC, cells 
were centrifuged to remove ethanol, and washed once with 2% BSA in PBS. The resulting 
cell pellet was resuspended in 400 µL of propidium iodide/RNAse solution (Immunostep, 
Salamanca, Spain). After 15 min incubation under dark at room temperature, cell suspensions 
were immediately analyzed by flow cytometry using a FACS-Calibur flow cytometer (BD 
Biosciences, San Jose, CA). To discriminate viable and dead cells and to exclude doublets, 
cells were appropriately gated by forward/side scattering and pulse width. Data were 
collected from at least 10,000 single cell events, stored in CellQuest software and analyzed 
using ModFit LT 3.0. 
 
Statistical analysis  
Data are presented as mean ± SD of at least three independent experiments. The 
significance of the results was statistically analyzed by one-way analysis of variance (ANOVA) 
with Tukey's multiple pairwise comparison, unless stated otherwise. Statistical significance 
was set at p < 0.05. 
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Chapter 4 
 
 Enhancing glioblastoma cell sensitivity to chemotherapeutics: a 
strategy involving survivin gene silencing mediated by gemini 
surfactant-based complexes 
 
 
The results included in this Chapter are part of the following article: Rita Q. 
Cruz, Catarina M. Morais,  Ana M. Cardoso, Sandra G. Silva, Maria L. Vale, 
Eduardo F. Marques, Maria C. Pedroso de Lima, Amália S. Jurado, 
“Enhancing glioblastoma cell sensitivity to chemotherapeutics: a strategy involving 
survivin gene silencing mediated by gemini surfactant-based complexes” 
Submitted for publication in Molecular Pharmaceutics. 
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4.1. Abstract 
Glioblastoma (GBM), the highest grade astrocytoma, is one of the most aggressive and 
challenging cancers to treat. The standard treatment is usually limited due to the intrinsic 
resistance of GBM to chemotherapy and drug non-specific effects. Therefore, new 
therapeutic strategies need to be developed to target tumor cells, sparing healthy tissues. In 
this context, the inhibitor-of-apoptosis protein (IAP) survivin emerges as an ideal target for a 
gene silencing approach, since it is sharply differentially expressed in cancer tissues. In this 
work, two different families of cationic gemini surfactants (bis-quat conventional and serine-
derived) were tested regarding their efficiency to deliver small interfering RNAs (siRNAs) in 
a human GBM cell line (U87), in order to select an effective siRNA anti-survivin carrier. 
Ultimately, a combined approach involving survivin downregulation mediated by siRNAs 
formulated in a serine-derived gemini surfactant-based vector and administration of the 
chemotherapeutic agents temozolomide and etoposide was employed, showing to be 
promising to sensitize GBM cells to chemotherapy. 
 
KEYWORDS: gemini surfactants, gene therapy, survivin, RNA interference, 
chemotherapy, temozolomide, etoposide, glioblastoma 
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4.2. Introduction 
Glioblastoma (GBM), a grade IV glioma (Adamson et al., 2009), is characterized by its 
propensity for proliferation and resistance to apoptosis, extensive angiogenesis and 
widespread invasion (Furnari et al., 2007).  Therefore, prognosis of GBM patients remains 
poor, with a median survival of only 12 to 15 months (Stupp et al., 2005; Zhang et al., 2012).  
For this reason, it is mandatory to improve the standard therapies or develop new 
therapeutic interventions. 
Survivin, a small inhibitor-of-apoptosis protein (IAP) overexpressed in GBM (George et al., 
2010), constitutes an attractive target for cancer therapies because it is rarely detected in 
normal tissues (Altieri, 2008; Duffy et al., 2007; Mita et al., 2008) and is highly expressed in 
tumors (Altieri, 2008). Although survivin has been proposed to act through inhibition of 
mitochondrial-dependent apoptosis, its primary function involves the regulation of the 
mitosis progression (Okada and Mak, 2004), playing also an important role in angiogenesis 
7,(Duffy et al., 2007; Ryan, B.; O’Donovan, N.; Duffyg, 2009) and chemoresistance (Mita et al., 
2008; Pennati et al., 2008).  
In this context, and considering that an apoptosis deficit renders tumors more chemo- 
and/or radio-resistant (Fesik, 2005), it is expected that a gene silencing approach, benefiting 
from RNA interference (RNAi) technology, targeting the anti-apoptotic protein survivin, can 
enhance cell susceptibility to apoptosis (Pai et al., 2006). Due to the extracellular and 
intracellular barriers that nucleic acids are unable to surpass by themselves, appropriate 
carriers are necessary to aid siRNAs to reach the cell cytoplasm, avoiding their degradation. 
To overcome the safety drawbacks of the highly immunogenic viral vectors (Mountain, 
2000), non-viral vectors, characterized by their simplicity and safety, have revealed to be a 
promising alternative, although their delivery efficiency still needs to be improved towards 
levels similar to those of their viral counterparts. 
In this regard, cationic gemini surfactants, which interact with the nucleic acids through 
electrostatic and hydrophobic interactions, have been shown to be highly efficient to deliver  
plasmid DNA (pDNA) (Bell et al., 2003; Cardoso et al., 2015b; Fielden et al., 2001; 
Rosenzweig et al., 2001). Gemini or dimeric surfactants are amphiphilic molecules 
characterized by a particular structure containing two identical polar headgroups and two 
identical hydrophobic chains, connected by a rigid or flexible spacer. This structure differs 
markedly from that of conventional monomeric surfactants, which have a single alkyl tail 
connected to a polar headgroup (Menger, Fredric and Keiper, 2000). The gemini structure 
imparts the compounds significant versatility, since molecules can be designed with different 
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number of carbons in the alkyl chains and in the spacer, as well as with different polar 
headgroups (Weihs et al., 2005); in turn, this translates into rich aggregation properties. 
Cationic gemini surfactants of the bis-quaternary ammonium salt (bis-quats) family (Figure 4.1 
A), commonly designated m-s-m (m and s standing for the number of carbon atoms in the 
hydrophobic chains and in the spacer group, respectively) (Cardoso et al., 2011) reveal 
multifaceted aggregation properties but can present some problems regarding 
biocompatibility and biodegradability (Pérez et al., 2007; Weihs et al., 2005). Therefore, novel 
classes of gemini surfactants, containing natural structural motifs (amino acids, sugars and 
lipids), have been designed to decrease the cytotoxicity associated with conventional bis-
quats (Brito et al., 2009; Silva et al., 2012; Singare and Mhatre, 2012). In this regard, serine-
derived gemini surfactants (Figure 4.1 B), have shown the ability to carry and deliver pDNA 
(Cardoso et al., 2015a), the transfection efficiency being dependent on surfactant structural 
features and on the presence of helper lipids (Cardoso et al., 2014, 2015a; Grosmaire et al., 
2002; Rosenzweig et al., 2001; Wang, C. et al., 2007). 
In the present study, the two different families of gemini surfactants (bis-quats and serine-
derived gemini surfactants) were studied regarding their potential to deliver siRNAs into the 
target cells. Subsequently, a combined strategy was employed, involving survivin gene 
silencing (mediated by the gemini surfactant-based formulation that showed to be the most 
efficient) and chemotherapeutics, with the overall objective of evaluating the ability of the 
survivin knockdown approach for sensitizing GBM cells to chemotherapy. 
Altogether, our work demonstrated that, through the employment of serine-derived gemini 
surfactants as anti-survivin siRNA carriers, a significant survivin knockdown was achieved, 
which rendered U87 cells more susceptible to the chemotherapeutics temozolomide and 
etoposide. 
 
Figure 4.1 - Schematic representation of the general structure of cationic gemini 
surfactants of the alkanediyl-α,ω-bis(alkyldimethylammonium bromide) family (A) and of the 
serine-derived gemini surfactant family (B).  
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4.3. Materials and methods 
Conventional gemini surfactants were synthesized by the method reported by Menger 
(Menger, F and Littau, 1993) and purified by recrystallization. Serine-derived gemini 
surfactants were synthesized by the method reported by Silva (Silva et al., 2012) and purified 
by column chromatography. The purity of the compounds was assessed by NMR and mass 
spectrometry, and the obtained critical micelle concentration values were found to be 
similar to those already reported in the literature (Burrows et al., 2007; Zana, 2002). 
The lipids 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE) and cholesterol (Chol) 
were purchased from Avanti Polar Lipids (Alabaster, AL). Lipofectamine RNAiMAX was 
acquired from Invitrogen (Carlsbad, CA). The siRNA duplex against GFP (siGFP) (sense: 5′-
GCAAGCUGACCCUGAAGUUCdTdT-3′) and the non-targeting siRNA duplex used as 
control (siMUT) (sense: 5′-UUCUCCGAACGUGUCACGUdTdT-3′) were synthesized by 
GeneCust (Dudelange, Luxembourg). The DY547-labeled non-targeting siRNA duplex 
(sense: 5′-UAAGGCUAUGAAGAGAUACdTdT-3′) and the anti-survivin siRNA duplex (5′-
GGACCACCGCAUCUCUACAdTdT-3′) were purchased from Dharmacon (Lafayette, CO, 
USA). Temozolomide and etoposide were acquired from Selleckchem (Munich, Germany) 
and stock solutions were prepared in DMSO (Sigma, Germany). Custom-designed primers 
for survivin and for the control HPRT-1 were acquired from Qiagen. The anti-survivin 
antibody (goat) was purchased from Santa Cruz (Santa Cruz Biotechnology, Inc., Heidelberg, 
Germany), the anti-β-actin antibody (mouse) and the secondary antibodies were acquired 
from Sigma (St. Louis, MO, USA). 
 
Cell lines and culturing conditions  
U87 human GBM cell line was kindly donated by Dr. Peter Canoll (Columbia University, 
New York, NY). A modified U87 cell line constitutively overexpressing GFP (U87-GFP) was 
derived from U87 cells, through infection with a lentiviral vector, as previously described 
(Costa et al., 2013). Both GBM cell lines were maintained in culture at 37º C, under a 
humidified atmosphere containing 5% CO2. Cells were grown in Dulbecco modified Eagle’s 
medium – high glucose (DMEM–HG; Sigma, St. Louis, MO, USA), supplemented with 10% 
(v/v) heat-inactivated fetal bovine serum (FBS; Sigma, St. Louis, MO, USA), 100 units/mL 
penicillin (Sigma) and 100 µg/mL streptomycin (Sigma). GBM cells grown in monolayer were 
detached using enzyme-free cell dissociation buffer at 50–70% confluence. For flow 
cytometry, QRT-PCR experiments and Western blot analysis, cells were plated at a density 
of 7x104 cells/well, in 1 mL of complete medium supplemented with FBS (10% v/v), in 12-well 
culture plates. For the assays involving the use of chemotherapeutical drugs (temozolamide 
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and etoposide), cells were seeded at a density of 6x103 cells/well, in 100 µL of complete 
medium, in 96-well plates. 
 
Gemini surfactant-based complexes 
Gemini surfactant-based complexes were prepared as previously described (Cardoso et al., 
2014). Briefly, an aqueous solution of gemini surfactant was prepared at 0.5 mM and filtered 
through 0.22 μm pore-diameter filters (Schleicher & Schuell, BioScience, Germany). DOPE 
and Chol were dissolved in chloroform, mixed at a 2:1 molar ratio and dried under vacuum 
in a rotatory evaporator. The resulting lipid film was hydrated with HBS (pH 11.0) to a final 
lipid concentration of 0.5 mM. The resulting multilamellar vesicles (MLVs) were then 
sonicated for 3 min, in a sonication bath. Binary complexes of gemini/siRNA were prepared 
by mixing an aliquot of the aqueous gemini solution with HBS and with a constant amount of 
the aqueous siRNA solution to obtain the desired surfactant/siRNA (+/-) charge ratios, 
followed by incubation at room temperature for 30 min. To produce ternary complexes 
(gemini/siRNA/helper lipids), a volume of a suspension of MLVs composed of DOPE:Chol 
(2:1 molar ratio) was added to surfactant/siRNA complexes, after 15 min of incubation, at 
room temperature, to obtain the desired surfactant/lipid molar ratios, followed by a further 
15 min incubation. 
 
Cell transfection 
Twenty-four hours after plating, cell medium was replaced with fresh medium (serum-free 
OptiMEM medium or DMEM medium containing 10, 20, 30 or 60% of serum). 
Gemini surfactant-based complexes prepared at different (+/-) charge ratios and containing 
siRNAs against the selected target mRNA were added to the cells at a final siRNA 
concentration of 50 nM. A non-targeting siRNA sequence (siMUT) was also employed to 
discriminate the target-gene silencing from non-specific effects. 
Lipofectamine RNAiMAX (Invitrogen, Carlsbad, CA), prepared according to manufacturer’s 
instructions, was used as a positive control for the delivery of the siRNA against survivin. 
Following 4 h incubation (in 5% CO2 at 37 °C), the medium was replaced with fresh medium 
containing FBS (10% v/v) and antibiotics. Cells were further incubated to allow gene 
silencing, for 20 or 44 h before the evaluation of cell viability and siRNA delivery by flow 
cytometry and mRNA quantification by QRT-PCR, and for 68 h before Western blot 
analysis. 
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Cell incubation with the drugs 
In order to determine if survivin silencing sensitized U87 cells to chemotherapeutic agents, 
24 h post-transfection, the medium was replaced by fresh medium and the drugs 
temozolomide (400 μM) and etoposide (1.5 μM), prepared in DMEM, were added to the 
cells. After 48 h of incubation of non-transfected and transfected cells with the drugs, cell 
viability was evaluated by the Alamar blue assay. 
 
Evaluation of cell viability  
Cell viability after gene silencing or after gene silencing plus drug incubation was assessed by 
a modified Alamar blue assay, as previously described (Konopka et al., 1996). An appropriate 
volume of resazurin dye in DMEM–HG medium (10% v/v) was added to the cells 48 h after 
transfection or incubation with the chemotherapeutic drugs. After color development, the 
absorbance was measured in a SPECTRAmax PLUS 384 spectrophotometer (Molecular 
Devices, Union City, CA), at 570 and 600 nm, according to the manufacturers’ instructions. 
Cell viability (as a percentage of control cells) was calculated according to the equation: 
 
Cell viability (% of control) = [(A570 - A600)/(A'570 - A'600)] x100 
     
where A570 and A600 are the absorbances of the treated cells, and A’570  and A’600 are 
those of the control (non-treated cells), at the indicated wavelengths. 
 
Determination of GFP silencing and expression by flow cytometry 
Flow cytometry was used to measure the relative fluorescence intensity of U87 cells after 
transfection with the different complexes. U87-GFP cells were employed to examine the 
level of GFP knockdown achieved with siGFP-complexes. 
After evaluating cell viability (48 h after transfection), cells were detached using enzyme-free 
cell dissociation buffer (5 min, at room temperature). Then, cells were washed by 
centrifugation (200 g, 4 ºC, 5 min) in 950 µL of ice-cold PBS and the resulting pellets were 
then resuspended in 200 µL of ice-cold PBS. The cell suspensions were immediately analyzed 
by flow cytometry using a FACS-Calibur flow cytometer (BD Biosciences, San Jose, CA). 
Live cells were gated by forward/side scattering from a total of 10,000 events and data were 
stored and analyzed using CellQuest software. The mean fluorescence was normalized with 
the fluorescence intensity of non-transfected cells. 
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Confocal microscopy studies 
Confocal microscopy was used to evaluate the ability of gemini surfactants to mediate 
efficient delivery of siRNAs into the cells, in the presence and absence of serum. 
24 h before transfection, U87 cells (2×104 cells/well) were plated onto 8-well chambered 
coverslips (Ibidi, Munich, Germany). After this period, the medium was replaced by fresh 
serum-free medium (0%) or medium containing 10% of serum and the complexes formulated 
with DY547-labeled siRNAs (50 nM) were added to the cells. 
After a further 4 h incubation, cells were rinsed twice with PBS and incubated with the DNA 
binding dye Hoechst 33342 (1 μg/mL, Molecular Probes, Eugene, OR) for 5 min (protected 
from light). Cells were washed twice with PBS and the fluorescence distribution was 
visualized using a Zeiss Axiovert confocal scanning microscope (Zeiss, Jena, Germany), under 
the 60⨯ oil immersion objective. 
 
RNA extraction and cDNA synthesis 
RNA was extracted from the whole-U87 cells (24 and 48 h after cell transfection with the 
target siSURV or siMUT), using the NucleoSpin RNA Isolation Kit (Macherey-Nagel, Düren, 
Germany), according to manufacturer’s recommendations. 
After RNA quantification, 300 ng of RNA (extracted from U87 cells 24 and 48 h after cell 
transfection) were converted to cDNA using the NZY First-Strand cDNA Synthesis Kit 
(NZYTech, Lisbon, Portugal), by applying the following protocol: 30 min at 50 ºC (cDNA 
synthesis) followed by 5 min at 85 °C (heat-inactivation of the reverse transcriptase). After 
transcription, the samples were further incubated for 20 min at 37 ºC with 0.5 µL of RNase 
H (from E.coli), to specifically degrade the RNA strand in RNA-cDNA hybrids.  
The resulting cDNA was further diluted 10 times with RNase-free water prior to 
quantification by qRT-PCR. 
 
Quantification of mRNA levels by QRT-PCR 
Quantitative PCR (QRT-PCR) was performed in a StepOnePlus Real-Time PCR System 
(Applied Biosystems, USA) using 96-well microtiter plates and the iQ SYBR Green Supermix 
Kit (Bio-Rad).  
Primers for the target gene (survivin) and housekeeping gene (HPRT1) were custom-
designed and acquired from Invitrogen. A master mix was prepared for each primer set, 
containing a fixed volume of SYBR Green Supermix and the appropriate amount of each 
primer, to yield a final concentration of 150 nM. For each reaction, performed in duplicate, 6 
µL of master mix were added to 4 µL of cDNA template. The reaction conditions consisted 
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of enzyme activation and well-factor determination for 1 min and 30 s at 95 ºC, followed by 
45 cycles for 10 s at 95 ºC (denaturation), 30 s at 55 ºC (annealing), and 30 s at 65 ºC 
(elongation). The melting curve protocol started immediately after amplification and 
consisted of 1 min heating at 55 ºC followed by 80 steps of 10 s, with an increase of 0.5 ºC 
in temperature at each step. Threshold values for threshold cycle (Ct) determination were 
generated automatically by the StepOne Software. Target gene expression was normalized 
to the amount of total RNA, by comparison with the endogenous reference gene. To 
determine gene knockdown, survivin gene expression in cells transfected with the target 
siSURV was compared with the survivin expression in cells treated with siMUT. Gene 
expression (mRNA fold change with respect to non-transfected control cells) was 
determined taking into consideration the different amplification efficiencies of both genes in 
all experiments. The selected housekeeping genes have an amplification efficiency similar to 
that of the target gene, which was determined according to the formula E = 10-1/S-1, where S 
is the slope of the standard curve obtained for each gene.  
 
Quantification of protein levels by Western blot 
Forty-eight hours after U87 cell transfection with siRNA complexes, protein was extracted, 
at 4 ºC, from 12-well microplates using RIPA lysis buffer (50 mM Tris pH 8.0, 150 mM NaCl, 
50 mM EDTA, 0.5% sodium deoxycholate, 1% Triton X-100) containing a protease inhibitor 
cocktail (Sigma), 10 μg/mL DTT and 1 mM PMSF. The protein content of the lysates was 
quantified using the Bio-Rad protein assay (Bio-Rad) and 30 μg of total protein were 
resuspended in a loading buffer (20% glycerol, 10% SDS, 0.1% bromophenol blue), 
denaturated upon 5 min incubation at 95 ºC and loaded onto a 12% polyacrylamide gel for 
electrophoretic separation. 
After electrophoresis, the proteins were blotted onto a PVDF membrane according to 
standard protocols. After 1 h of membrane blocking in 5% nonfat milk, the membrane was 
incubated with the primary antibody (anti-survivin 1:200, Santa Cruz Biotechnology, Inc., 
Heidelberg, Germany) overnight, at 4 ºC. Following this time period, the membrane was 
washed three times with TBS/T (25 mM Tris-HCl, 150 mM NaCl, 0.1% Tween) and 
incubated with the appropriate secondary antibody (1:10000) for 2 h, at room temperature. 
Then, the membrane was washed three times with TBS/T and incubated with the enzyme 
substrate ECF (alkaline phosphatase substrate; 20 μL of ECF/cm2 of membrane) for a 
maximum of 5 min, at room temperature. Fluorescence detection was achieved at 570 nm 
using a ChemiDocTM Touch Imaging System (Bio-Rad). Equal protein loading was shown by 
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reprobing the membrane with an anti-β-actin antibody (1:1000, Sigma) and with the 
appropriate secondary antibody. Prior to membrane reprobing, the blots were washed in 
40% methanol for 30 min, followed by a fast wash with Milli-Q water. The membrane was 
then washed with a glycine solution (0.1 M pH 2.5) for 40 min, further washed three times 
with TBS/T and blocked for 1 h in 5% nonfat milk. 
The analysis of band intensity was performed using ImageJ Software (Wayne Rasband 
National Institutes of Health, USA), and the survivin band intensity was normalized to β-actin 
in each experiment, in order to correct variations in the total protein content.  
 
Physico-chemical characterization of the complexes: size, zeta potential and 
siRNA protection determination 
The hydrodynamic size distribution of the ternary complexes of surfactant, siRNA and 
helper lipids was evaluated by dynamic light scattering (DLS). Immediately before analysis, 
the complexes were prepared as described above and diluted in HBS. The assay was 
performed using a Submicron Particle Size Analyzer, Beckman Coulter N4 Plus, at 25 ºC.  
Zeta potential measurement of the complexes was performed in the aqueous buffer HBS, at 
25 °C, using a Zetasizer Nano ZS, ZN 3500, with a 532 nm laser (Malvern Instruments, UK). 
The complexes were prepared immediately before analysis, placed in the measuring cell and 
an electric current of 3.0 mA was applied.  
PicoGreen intercalation assay was used to evaluate the degree of siRNA protection 
conferred by the delivery system. Complexes containing 14 pmol of siRNA were prepared in 
a total volume of 100 μl of HBS. After 30 min of incubation, at room temperature, 
complexes were transferred to a 96-well (black walled) plate (Corning, NY, USA) and 100 μl 
of PicoGreen (Molecular Probes, Eugene, OR), diluted according to the manufacturer's 
instructions (1:200 dilution in HBS buffer), were added to each well. Following an incubation 
period of 5 min, at room temperature, PicoGreen fluorescence, which is directly 
proportional to the amount of accessible/free nucleic acid, was measured using a 
SPECTRAmax Gemini EM fluorimeter (Molecular Devices, Union City, CA). The excitation 
and emission wavelengths were set at 485 and 520 nm, respectively. The fluorescence 
intensity was measured immediately after complex preparation at 25 ºC and 37 ºC, and 
every 10 min for the period of 1 h at 37 ºC. The amount of siRNA available to interact with 
the probe, expressed as a percentage of the maximum fluorescence obtained with naked 
siRNA, was determined according to the Equation: 
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% of free siRNA = [(F- F0)/( F100 - F0)] x 100 
 
where F is the fluorescence intensity measured after adding the PicoGreen solution to the 
complexes, F100 (corresponding to 100% of free siRNA) represents the maximum 
fluorescence intensity, obtained using naked siRNA in the same amount as that associated 
with the complexes, F0 (corresponding to 0% of free siRNA) is the residual fluorescence 
intensity, obtained in the absence of siRNA, which represents the maximum protection of 
the nucleic acid. 
 
Statistical Analysis 
Data are presented as mean ± SD of at least three independent experiments. The 
significance of the results was statistically analyzed by one-way analysis of variance (ANOVA) 
with Tukey's multiple pairwise comparison, unless stated otherwise. Statistical significance 
was set at p < 0.05. 
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4.4. Results 
4.4.1. GFP silencing mediated by gemini surfactant-based complexes and 
cytotoxicity   
In order to select an efficient vehicle for siRNAs, used in this work to promote survivin 
downregulation, studies were initially performed to evaluate the ability of bis-quats and 
serine-derived gemini surfactants to mediate GFP gene silencing in U87 GBM cells, stably 
transfected to constitutively express GFP (U87-GFP). Flow cytometry analysis was used to 
assess GFP expression upon cell transfection with gemini surfactant-based complexes 
carrying anti-GFP siRNA. Parallel cell viability experiments were performed using a modified 
Alamar blue assay, to evaluate the cytotoxicity associated with the transfection process. 
Figure 4.2 shows that complexes containing the cationic gemini surfactant with m=16 and 
s=2 mediated a significant reduction of GFP expression, displaying the highest transfection 
efficiency (45.5% of GFP silencing) at the 8/1 (+/-) charge ratio, without causing significant 
unspecific effects (deduced from the transfection assay in which an oligonucleotide with a 
scrambled sequence was used, siMUT) or cytotoxicity (86.7% of cell viability). In contrast to 
16-2-16, other gemini surfactants of the bis-quat family with different tail lengths (m=12, 14 
and 18) or with longer spacers (s=5 or 10) showed to be ineffective in promoting GFP 
silencing (Figure S4.1, Supplementary data). 
 
 
 
 
 
 
 
 
 
 
Figure 4.2 - Mean fluorescence intensity (A) and viability (B) of U87-GFP cells transfected 
with complexes of 16-2-16/siGFP (gray bars) or 16-2-16/siMUT (black bars), at the indicated 
(+/−) charge ratios. Results of GFP expression are presented with respect to that of a 
control (nontreated cells, 80% of which express GFP), taken as 100%. Cell viability results 
are presented as a percentage of the control (nontreated cells, more than 98% of which are 
57 
 
viable), taken as 100%. The results represent the mean ± SD obtained from three 
independent experiments. Formulations containing siGFP were compared with the 
corresponding formulation containing siMUT (** p<0.01). 
 
Serine-derived gemini surfactants with a 5-carbon spacer, differing in the alkyl tail length 
(m=12, 14, 16 or 18) showed to be unable per se to mediate efficient gene silencing in U87-
GFP cells, regardless of the (+/ −) charge ratio (Figure S4.2, Supplementary data). Therefore, 
the binary complexes (gemini surfactant/siGFP) that induced less cytotoxicity (m=14 and 18) 
were combined with a mixture of DOPE and Chol, used as helper lipids (HL), in an attempt 
to improve the ability of gemini surfactant-based complexes to mediate gene silencing. 
Figure 4.3 shows the mean fluorescence intensity (A) and viability (B) of U87-GFP cells 
obtained upon incubation with binary or ternary siRNA complexes based on (14Ser)2N5 and 
(18Ser)2N5, at the 8/1 and 12/1(+/-) charge ratios and at different HL:gemini surfactant 
molar ratios. A similar tendency for enhanced transfection efficiency with the increase of the 
HL:surfactant molar ratio (to a maximum of 4:1), was observed for both gemini sufactants. In 
fact, (14Ser)2N5/siRNA/HL complexes at the 4:1 HL:surfactant molar ratio and at the 8/1 
and 12/1 (+/-) charge ratios displayed the highest transfection efficiency (50% of GFP 
silencing), without causing significant unspecific effects (as inferred by comparing with siMUT 
transfection). In addition, at the 12/1 (+/-) charge ratio the complexes induced less 
cytotoxicity than at the 8/1 (+/-) charge ratio (89.8 and 72.1% of cell viability, respectively). 
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Figure 4.3 - Mean fluorescence intensity (A) and viability (B) of U87-GFP cells, transfected 
with complexes of (mSer)2N5/siGFP (white and gray bars) or (mSer)2N5/siMUT (black bars), 
prepared at the 8/1 and 12/1 (+/-) charge ratios, combined with the helper lipids DOPE:Chol 
(2:1), at the indicated molar ratios of HL: gemini surfactant (HL:(mSer)2N5). Results of GFP 
expression are presented with respect to that of a control (nontreated cells, 80% of which 
express GFP), taken as 100%. Cell viability results are presented as a percentage of the 
control (nontreated cells, more than 98% of which are viable), taken as 100%. The results 
represent the mean ± SD obtained from three independent experiments. Formulations 
containing siGFP were compared with the corresponding formulation containing siMUT 
(black bars) (** p<0.01, *** p<0.001).  
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In order to evaluate the capacity of the complexes to overcome the inhibitory effect of 
serum on transfection, cells were incubated with the complexes in medium containing 
increasing amounts of serum (10, 20, 30 and 60%) during the period of transfection (4 h). 
Figure 4.4A shows that serum inhibited transfection mediated by 16-2-16-based complexes, 
in contrast to the (14Ser)2N5-based formulation, which maintained its transfection ability 
unchanged up to 20% serum (Figure 4.4C). In either case, the presence of serum did not 
affect cell viability, as shown in Figure 4.4B and D for cells transfected with 16-2-16-based 
and (14Ser)2N5-based complexes, respectively. 
Since the silencing efficiency of bis-quat-based complex (16-2-16/siRNA) revealed to be 
limited by the presence of serum, serine-derived gemini surfactant-based complexes 
((14Ser)2N5/siRNA/HL) were selected for the subsequent experiments. 
 
 
Figure 4.4 - Mean fluorescence intensity (A and C) and viability (B and D) of U87-GFP cells 
transfected with binary complexes of 16-2-16/siRNA (at the 8/1 (+/-) charge ratio) (A, B) or 
with ternary complexes of (14Ser)2N5/siRNA/HL (at the 12/1 (+/-) charge ratio and 4:1 
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HL:surfactant molar ratio) (C, D). Cells were incubated for 4 h with complexes in serum-
free medium (0%) or with medium containing 10, 20, 30 or 60% of serum. Then, the medium 
was replaced by fresh complete medium and, after a further 44 h incubation, data were 
collected. Results of GFP expression are presented with respect to that of a control 
(nontreated cells, 80% of which express GFP), taken as 100%. Cell viability results are 
presented as a percentage of the control (nontreated cells, more than 98% of which are 
viable), taken as 100%. The results represent the mean ± SD obtained from three 
independent experiments. Formulations containing siGFP were compared with the 
corresponding formulation containing siMUT (black bars) (** p<0.01, *** p<0.001). 
 
4.4.2. Cellular uptake of (14Ser)2N5/siRNA/HL complexes and 
intracellular distribution of siRNA-DY547 
Figure 4.5 shows the intracellular distribution of DY547-labeled siRNAs (red) following 
transfection of U87 cells mediated by the (14Ser)2N5/siRNA/HL complexes. Confocal 
microscopy images confirm that, 4 h after transfection, siRNAs efficiently reach the cell 
cytoplasm, both in the absence and presence of serum. However, particle cytoplasmic 
distribution in cells transfected in the absence of serum appears in a punctuated pattern 
indicating that (14Ser)2N5/siRNA/HL complexes may be imprisoned in endocytic vesicles, 
whereas in the presence of serum the distribution pattern is more diffuse and homogeneous 
throughout the cytoplasm, suggesting that, under these conditions, the complexes were able 
to escape from the endosomes or, alternatively, were internalized via non-endocytic 
pathways.  
 
61 
 
 
Figure 4.5 - Representative confocal microscopy images of the siRNA distribution in U87 
cells, taken 4 h after transfection with (14Ser)2N5/siRNA/HL complexes. U87 cells were 
transfected in serum-free medium (0%) or in medium containing 10% of serum with 
complexes containing DY547-labeled siRNA (red). Cell nuclei were labeled blue using the 
DNA-binding Hoescht 33342 dye and cell limits are visible in differential interference 
contrast (DIC) images. Non-treated U87 cells (NTC) are shown as a control. 
 
To clarify if endocytosis is involved in the cellular uptake of (14Ser)2N5/siRNA/HL 
complexes, U87-GFP cells were transfected in the presence and absence of serum, at 37 and 
4 ºC, and GFP silencing was evaluated by flow cytometry, as previously described (Figure 
4.6). In the absence of serum, the reduction of GFP mean fluorescence intensity promoted 
by siGFP complexes at 4 ºC was not significantly different from that induced by the control 
siMUT complexes, as opposed to what was found at 37 ºC (Figure 4.6A). In contrast, in the 
presence of 10% serum, a specific GFP silencing was obtained at both 4 and 37 ºC. In both 
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conditions (0 and 10% serum), a significant decrease of the specific GFP silencing was found 
at the low temperature as compared to that observed at the physiological temperature 
(Figure 4.6B), thus indicating a contribution of temperature-dependent, most likely 
endocytic, pathways for the internalization of the complexes. However, the observation that 
at the low temperature GFP silencing was not completely abolished (Figure 4.6A), suggests 
that non-endocytic mechanisms are also involved in the cell uptake of (14Ser)2N5/siRNA/HL 
complexes. 
 
 
Figure 4.6 - (A) Mean fluorescence intensity of U87-GFP cells transfected with the ternary 
complexes (14Ser)2N5/siGFP/HL (white and gray bars) or (14Ser)2N5/siMUT/HL (black 
bars), at the 12/1 (+/-) charge ratio and 4:1 HL:surfactant molar ratio, in the absence and 
presence of serum, at 37 or 4 ºC. (B) Mean fluorescence intensity of U87-GFP cells 
transfected with the complexes (14Ser)2N5/siGFP/HL, expressed in percentage of the mean 
fluorescence intensity of the same cells transfected with the complexes 
(14Ser)2N5/siMUT/HL, in the absence and in the presence of serum, at 37 or 4 ºC. Cells 
were incubated for 2 h with the complexes in serum-free medium (0%) or with medium 
containing 10% of serum, at 37 or 4 ºC, as indicated in the figure. Then, the medium was 
replaced by fresh complete medium and, after a further 44 h incubation, data of GFP 
expression were collected and presented with respect to that of a control (nontreated cells, 
80% of which express GFP), taken as 100%, (A), and as a percentage of the corresponding 
formulation containing siMUT (B). The results represent the mean ± SD obtained from three 
independent experiments. Pairwise comparisons were performed (A) for the reduction of 
GFP mean fluorescence intensity promoted by formulations containing siGFP and siMUT (** 
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p<0.01, *** p<0.001) and for the silencing ability of the formulation containing siGFP 
(expressed in percentage of that containing siMUT) in cells incubated at 4 ºC and at 37 ºC (# 
p<0.05, ## p<0.01, using the unpaired t-test). 
 
4.4.3. Physico-chemical characteristics of (14Ser)2N5-based complexes 
Gemini surfactant-based complexes were characterized with respect to their hydrodynamic 
diameter, surface charge and ability to confer protection to the carried siRNAs. 
Complexes of (14Ser)2N5/siRNA/HL, prepared at the 12/1 (+/-) charge ratio, displayed an 
average diameter of 679 nm, although with a polydisperse distribution (PI of 0.655), and a 
neutral surface charge (Table 4.1). 
 
Table 4.1 - Physico-chemical characteristics of (14Ser)2N5/siRNA/HL complexes. 
 
Complex 
 
 
Charge 
ratio (+/-) 
 
HL:surfactant 
molar ratio 
 
Hydrodynamic 
diameter / nm 
 
PD 
index 
 
 
Zeta potential 
/ mV 
 
(14Ser)2N5/
siRNA/HL 
 
 
12/1 
 
4:1 
 
679 ± 84 
 
0.655 ± 
0.039 
 
 
+0.4 ± 1.0 
 
The siRNA protection conferred by the (14Ser)2N5/HL carrier was evaluated in the absence 
and presence of serum (10 and 30%) at 25 and 37 ºC (Figure 4.7). At room temperature and 
in the absence of serum, approximately 50% of the siRNA was inaccessible to the probe, 
thus indicating a moderate nucleic acid protection (Figure 4.7A), which was maintained for at 
least one hour when the temperature was increased to 37 °C (Figure 4.7B). In the presence 
of serum (10 and 30%), siRNA became more accessible to the fluorescent probe, indicating 
complex destabilization (Figure 4.7A). The disassembly of the complexes and consequent 
exposure of the siRNA to the probe, at 37 ºC and in the presence of serum, revealed to be 
progressive, being completed after 50 min (Figure 4.7B). 
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Figure 4.7 - Effect of the temperature and the presence of increasing amounts of serum on 
siRNA protection conferred by (14Ser)2N5/HL, as assessed by the PicoGreen intercalation 
assay. Complexes were incubated in HBS containing 0, 10 or 30% of serum and probe 
accessibility to siRNAs was measured immediately after complex preparation at 25 ºC and 
37 ºC, and after 60 min at 37 ºC (A), and every 10 min during a period of 60 min, at 37 ºC 
(B).  Data are representative of three independent experiments. Pairwise comparisons were 
performed in (A) between complexes incubated in the presence of serum and the 
corresponding complexes incubated in its absence (white bars) (* p<0.05, ** p<0.01). 
 
4.4.4. Survivin downregulation and effects on cell viability 
Transfection experiments using (14Ser)2N5/siRNA/HL complexes, prepared at the 12/1 (+/-) 
charge ratio, were performed in order to assess their ability to mediate downregulation of 
an endogenous protein in U87 cells in the presence of serum. For this purpose, siRNA 
against the messenger RNA (mRNA) of survivin (siSURV), an anti-apoptotic protein 
overexpressed in cancer, was used to transfect the cells and survivin mRNA levels were 
evaluated by qRT-PCR. Upon transfection with (14Ser)2N5/siSURV/HL complexes in medium 
containing 10% of serum, U87 cells presented decreased survivin mRNA levels, by 
approximately 50 and 60%, 24 and 48 h after transfection, respectively (Figure 4.8 A and C, 
respectively). In contrast, in the absence of serum, survivin knockdown was not significant 
when compared to that obtained using complexes prepared with the non-target siRNA 
(siMUT). The transfection efficiency of (14Ser)2N5-based complexes was compared to that 
of the commercially available transfection reagent RNAiMAX. Although being able to reduce 
in 80% the survivin mRNA levels, RNAiMAX transfection resulted in ca. 50% of unspecific 
effects, as indicated by the silencing effect observed with RNAiMAX/siMUT (Figure 4.8 C). 
Anti-survivin siRNA delivery mediated by either surfactant-based complexes or RNAiMAX 
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did not result in any impact on U87 cell viability, neither 24 (Figure 4.8B) nor 48 h (Figure 
4.8D) post-transfection. 
 
 
Figure 4.8 - Survivin mRNA levels (A and C) and viability (B and D) of U87 cells 24 (A and 
B) and 48 h (C and D) post-transfection with complexes of (14Ser)2N5/siRNA/HL, at 12/1 
(+/-) charge ratio and combined with helper lipids at the 4:1 (HL:surfactant) molar ratio 
(white and black bars, for siSURV and siMUT, respectively), or with RNAiMAX/siRNA (gray 
and dotted bars for siSURV and siMUT, respectively). Transfection was performed in  
serum-free medium and in medium containing 10% of serum, as indicated in the figure. For 
determination of survivin mRNA levels, RNA was recovered from U87 cells 24 or 48 h after 
transfection and converted to cDNA, which was analyzed by qRT-PCR. Survivin mRNA 
levels, presented as fold change with respect to nontreated control cells, was determined by 
the ΔΔCt method, as described in Materials and Methods. Cell viability results are presented 
as a percentage of the control (nontreated cells, more than 98% of which are viable), taken 
as 100%. Results represent the mean ± SD obtained from three independent experiments. 
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Survivin mRNA levels of cells transfected with formulations containing anti-survivin siRNA 
(white and gray bars) were compared with those of cells transfected with the corresponding 
formulation containing siMUT (black and dotted bars) (* p<0.05, *** p<0.001). 
 
The reduction of survivin mRNA levels, mediated by (14Ser)2N5/siRNA/HL complexes, in 
medium containing 10% of serum, was accompanied by the decrease of survivin expression, 
analyzed by Western blot, 72 h post-transfection (Figure 4.9). In fact, survivin mRNA 
silencing mediated by (14Ser)2N5/siSURV/HL complexes was able to reduce survivin levels to 
60% of those observed for nontreated control cells. In addition, no decrease in survivin 
expression was observed in cells transfected with the control complexes prepared with 
siMUT (96% survivin expression), ruling out any unspecific effects.  
 
 
Figure 4.9 - Representative image of survivin knockdown mediated by 
(14Ser)2N5/siRNA/HL complexes in U87 cells and evaluated by Western blot analysis 72 h 
after transfection. U87 cells were transfected with (14Ser)2N5/siRNA/HL complexes 
prepared with siRNA targeting survivin mRNA (siSURV) or with a non-targeting siRNA 
(siMUT).Non-transfected cells (NTC) are shown as control and β-actin levels are shown as 
reference for equal amount of protein loaded onto the gel.  
 
4.4.5. Effect of the combination of chemotherapeutics with survivin gene 
silencing 
A combined therapy approach consisting of survivin silencing and chemotherapeutic 
administration was used to assess the potential of the survivin knockdown strategy to 
sensitize GBM cells to the anti-cancer drugs temozolomide (TMZ) and etoposide (ETO). For 
this purpose, survivin silencing with (14Ser)2N5/siRNA/HL complexes was followed by 48 h 
incubation with TMZ or ETO, and the viability of U87 cells was evaluated using the Alamar 
blue assay. As observed in Figure 4.10, cell viability was significantly decreased in cells 
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transfected with anti-survivin siRNA and treated with TMZ or ETO, as compared to cells 
that were only transfected or treated with each drug alone. TMZ treatment induced only 
10% reduction in cell viability, whereas its combination with survivin silencing resulted in 
approximately 50% of viability loss. Similar results were obtained when cells were incubated 
with ETO, which per se only induced 5% of viability loss, while in cells previously transfected 
with anti-survivin siRNA, it induced a viability loss of 40%. The combined treatment involving 
survivin silencing and TMZ or ETO incubation showed a synergistic effect, as concluded by 
the determined Bliss interaction index (BII), which was higher than 1 (Figure 4.10 B and D) 
(Olaussen et al., 2009). Parallel transfection experiments with siMUT and drug incubation 
resulted in a BII around 1, which indicates that cytotoxicity induced by this combination is 
additive, i.e. results from the sum of the effects of each agent alone. 
 
Figure 4.10 - Viability of U87 cells (A and C), assessed by the Alamar Blue assay, 72 h after 
transfection with siRNA anti-survivin (siSURV) or with siMUT and/or cell incubation with 
68 
 
the chemotherapeutical drugs temozolamide (TMZ) (A) or etoposide (ETO) (C), and Bliss 
interaction index  (B and D) determined for the combined effects on cell viability of survivin 
silencing plus treatment with each drug. Cells were transfected, for 4 h, with 
(14Ser)2N5/siRNA/HL complexes and, after an additional period of 20 h, cells were 
incubated with 400 µM TMZ (A) or 1.5 µM ETO (C), for 48 h. Results, representative of at 
least three independent experiments, are expressed as a percentage of the nontreated 
control cells. Combined treatment (dotted bar) was compared with the single drug 
treatment (gray bar) (** p<0.01, *** p<0.001). 
 
69 
 
 
4.5. Discussion  
One of the most concerning hallmarks of GBM is its ability to acquire chemoresistance, 
which results in a decreased effectiveness of both TMZ, an alkylating agent used as the first-
line treatment of GBM, and ETO, an inhibitor of Topoisomerase II enzyme (Sevim et al., 
2011) that has also been tested in patients with malignant gliomas. Tumor formation, 
chemoresistance and radioresistance are phenomena mainly emerging from the combination 
of genetic and epigenetic events leading to oncogene activation and tumor suppressor gene 
inactivation. In this context, the deregulation of anti-apoptotic proteins assumes also a 
crucial relevance (Delbridge, Valente and Strasser, 2012). Survivin, a 16.4 kDa anti-apoptotic 
protein overexpressed in GBM (George et al., 2010), appears as an extremely promising 
therapeutic target due to its role in mediating cell proliferation and survival and also in 
inducing chemoresistance (Mita et al., 2008; Pennati et al., 2008).  
In this work, a combined strategy involving survivin silencing followed by treatment with the 
anti-cancer drugs TMZ or ETO, which have been used as first-line agents in the treatment of 
GBM, was developed in order to evaluate the efficiency of the knockdown of that oncogenic 
protein in sensitizing GBM cells to chemotherapeutics. Previous studies in our laboratory 
using a similar approach have demonstrated an enhancement of the cytotoxicity exerted by 
doxorubicin and vinblastine in two human cancer cell lines, HeLa (epithelial cervical 
carcinoma cells) and A549 (breast adenocarcinoma cells), upon survivin knockdown 
mediated by a commercial transfection reagent (Trabulo et al., 2011). In the present work, a 
gemini surfactant-based complex combining efficient transfection with low cytotoxicity in 
GBM cells, was tentatively selected as an anti-survivin siRNA delivery system. With this 
purpose, an extensive study was performed using two families of gemini surfactants—bis-
quats (m-s-m) and serine-derived gemini surfactants—that had previously shown to 
efficiently mediate plasmid DNA delivery in HeLa cells (Cardoso et al., 2011, 2014, 2015a), 
but whose ability to deliver siRNAs and mediate gene silencing had not been explored. Two 
gemini surfactant-based formulations, the binary 16-2-16/siRNA and the ternary 
(14Ser)2N5/siRNA/HL complexes, yielded a remarkable potential to mediate silencing of a 
reporter gene (GFP), reducing in ca. 50% the green fluorescence of U87-GFP cells (Figures 
4.2 and 4.3), without presenting cytotoxicity or unspecific silencing effects (as evaluated with 
the corresponding complexes formulated with an non-targeting siRNA – siMUT). While 16-
2-16/siRNA complexes were able to efficiently mediate gene silencing in the absence of 
serum, although not in its presence (Figures 4.2 and 4.4), binary complexes of 
(14Ser)2N5/siRNA were completely ineffective even in the absence of serum. However, the 
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combination of the latter with the helper lipids DOPE and Chol resulted in an enhancement 
of transfection efficiency, which was independent of serum presence (up to 20% of FBS). The 
ability of the helper lipids DOPE and cholesterol to enhance the efficiency of conventional 
and serine-derived surfactants was previously shown (Cardoso et al., 2014, 2015a) and 
justified by the propensity of the non-bilayer lipid DOPE to adopt an inverted hexagonal 
phase, hence promoting nucleic acid escape from the endosome (Hafez and Cullis, 2001; Hui 
et al., 1996; Koltover et al., 1998; Siegel and Epand, 1997; Zuhorn et al., 2005), and the 
potential of cholesterol to stabilize the complexes and to prevent their interaction with 
serum proteins (Crook et al., 1998; Faneca, Simões and Lima, de, 2002; Maslov and Zenkova, 
2011; Semple et al., 1996). 
The serine-derived gemini surfactant-based complexes (14Ser)2N5/siRNA/HL were selected 
for the subsequent studies due to their ability to maintain biological activity even in the 
presence of serum, thus overcoming this important barrier to transfection. Noticeably, 
confocal microscopy images of cells transfected in the absence or in the presence of 10% 
FBS with (14Ser)2N5/siRNA/HL complexes prepared with fluorescently labeled siRNAs 
(Figure 4.6) showed a punctuated distribution of these complexes in the cytoplasm of cells 
transfected in the absence of serum, whereas in its presence, particle distribution showed a 
diffuse intracellular pattern. This behavior could indicate that the presence of serum in the 
transfection medium might alter the pathway of complex uptake, since the punctuated 
pattern has been assigned to particle entrapment in intracellular vesicles, most likely 
resulting from the endocytic uptake of the complexes. On the other hand, the diffuse 
fluorescence distribution observed in the presence of serum may suggest that the complexes 
have been internalized by non-endocytic pathways, which is consistent with the fact that 
silencing was not decreased to residual values at 4 ºC (Figure 4.6). Alternatively, it is possible 
that endosomal escape of the complexes and dissociation of siRNAs, which have to be free 
in order to exert their silencing effect, has been facilitated in the presence of serum. In fact, 
an early complex disassembly subsequent to the interaction of the complexes with serum 
components in cell medium is suggested by the siRNA accessibility to the fluorescent probe 
PicoGreen evaluated over 1 h period (Figure 4.7). The partial disassembly of the complexes 
promoted by their interaction with serum components and potential alterations of their 
architecture may facilitate the intracellular release of the nucleic acids. Interestingly, the 
same formulation containing anti-survivin siRNA, i.e. (14Ser)2N5/siSURV/HL, promoted a 
significant decrease of survivin mRNA levels in the presence of serum, but not in its absence, 
thus confirming the importance of siRNA release into the cytoplasm for the success of gene 
silencing. 
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Aiming at a future therapeutic application of the (14Ser)2N5/siRNA/HL complexes for gene 
silencing, further characterization of these complexes was performed. The hydrodynamic 
diameter and surface charge of the complexes are physical properties that affect the 
efficiency of the delivery. In fact, although blood capillaries display a 5 µm diameter (Jacobs, 
Kayser and Muller, 2001), particles larger than 200 nm are not compatible with in vivo 
intravenous administration, being sequestered by the phagocytic system (Gupta and Gupta, 
2005). In this regard, although serine-based complexes were found to display a mean 
diameter larger than this cutoff value (679 nm, see Table 4.1), other routes of administration 
can be used for the delivery of siRNA complexes, namely intraperitoneal, intramuscular or 
subcutaneous routes, which are not limited by the size of the particle (Donkuru et al., 2010; 
Neves et al., 2006; Pfeiffer et al., 2006). In addition, these complexes present a surface charge 
close to neutrality (Table 4.1), a feature that has been considered ideal to avoid the immune 
system activation (Li, S. and Huang, 2008).  
The therapeutic potential of gemini-based complexes containing siRNAs was tested using 
siRNAs against survivin, a protein with a recognized role in tumor cell proliferation and 
viability (Duffy et al., 2007; Mita et al., 2008; Pennati et al., 2008). A significant survivin mRNA 
silencing (60%, with respect to non-transfected control cells) was observed 24 h after 
transfection (Figure 4.8) and downregulation of the protein levels (to 60% as compared to 
non-transfected control cells) was observed 72 h post transfection (Figure 4.9). Although 
survivin silencing per se was unable to impair U87 cell viability, the successful decrease of 
survivin levels showed to be sufficient for rendering cells more susceptible to a second 
insult. In fact, cells subjected to the combined approach consisting of survivin knockdown 
followed by treatment with the chemotherapeutic agents TMZ or ETO displayed a drastic 
decrease of viability as compared to those exclusively treated with each drug at the same 
concentration. These results indicate a synergistic effect on the viability of cells whose 
survivin levels had previously been modulated, when compared to that on cells solely 
incubated with the drugs (Figure 4.10). On the other hand, cell transfection with the 
formulation containing the non-targeting siRNA, combined with drug treatment, induced a 
mere additive cytotoxic effect, which confirms that it was, indeed, the silencing of the anti-
apoptotic protein that dramatically impaired the intrinsic chemoresistance of U87 cells. 
Overall, these results indicate that cationic gemini surfactants are capable of efficiently 
delivering siRNA into the cell cytoplasm, even in the presence of serum. The most promising 
gemini-based complexes, (14Ser)2N5/siRNA/HL, were able to silence the expression of the 
anti-apoptotic protein survivin, which resulted in a synergistic effect in terms of cytotoxicity 
induced by the chemotherapeutic drugs TMZ and ETO. Ultimately, this strategy reveals the 
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potential to improve the therapeutic efficacy of anti-cancer drugs and to allow the reduction 
of chemotherapeutic doses currently used to tackle GBM, thus also minimizing the side 
effects associated with cancer treatment. 
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4.6. Supplementary data 
 
 
 
 
Figure S4.1 - Mean fluorescence intensity (A and C) and viability (B and D) of U87-GFP 
cells transfected with conventional cationic gemini surfactants-based complexes, differing in 
the tail and spacer lengths, as indicated in the figure. m-s-m/siGFP (white and gray bars) and 
m-s-m/siMUT (black bars) were tested at the indicated (+/−) charge ratios. Results of GFP 
expression are presented with respect to GFP expression of a control (nontreated cells, 
80% of which express GFP), taken as 100%. Cell viability results are presented as a 
percentage of the control (nontreated cells, more than 98% of which are viable), taken as 
100%. The results represent the mean ± SD obtained from three independent experiments. 
Formulations containing siGFP were compared with the corresponding formulation 
containing siMUT (** p<0.01). 
 
Figure S4.2 - Mean fluorescence intensity (A) and viability (B) of U87-GFP cells transfected 
with serine derived cationic gemini surfactants-based complexes, differing in the tail length, 
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as indicated in the figure. (mSer)2N5/siGFP (white and gray bars) and (mSer)2N5/siMUT 
(black bars) were tested at the indicated (+/−) charge ratios. Results of GFP expression are 
presented with respect to GFP expression of a control (nontreated cells, 80% of which 
express GFP), taken as 100%. Cell viability results are presented as a percentage of the 
control (nontreated cells, more than 98% of which are viable), taken as 100%. The results 
represent the mean ± SD obtained from two independent experiments. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 5 
 
 Cisplatin delivery to glioblastoma cells mediated by serine-derived 
gemini surfactant/DNA complexes 
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to glioblastoma cells mediated by serine-derived gemini surfactant/DNA 
complexes”. 
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5.1. Abstract 
Cisplatin is a chemotherapeutic drug that has a long history of use in the treatment of brain 
tumors, but whose therapeutic potential is limited by the mechanisms of DNA repair. 
Mitochondria, which play a crucial role in cell apoptosis, have been actively studied as a 
potential target for anti-cancer drugs, including those that interfere with DNA, owing to 
mitochondria dysfunctional nucleotide excision repair mechanisms. Nevertheless, 
mitochondrial DNA is highly inaccessible due to the double-membrane that surrounds 
mitochondria, emphasizing the need for designing vectors that can circumvent this barrier. In 
this work, a cationic serine-derived gemini surfactant that showed to be able to carry a 
plasmid DNA to mitochondria, mediating mitochondrial expression of GFP, in the human 
recurrent glioblastoma cell line DBTRG-05MG, was employed to deliver cisplatin 
intercalated in plasmid DNA to those organelles. Comparative studies on the cytotoxicity 
induced by complexed and free cisplatin revealed that gemini surfactant-based complexes 
carrying cisplatin to mitochondria is a promising strategy to fight the intrinsic resistance of 
glioblatoma to chemotherapy. Moreover, since cisplatin did not impair the translation of 
plasmid DNA by mitochondria, an innovative therapeutic approach based on gene therapy 
combined with conventional anti-cancer drugs is proposed in this study to eradicate 
glioblastoma recurrence. 
 
KEY WORDS: serine, gemini surfactants, cisplatin, mitochondria, chemotherapy, 
glioblastoma 
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5.2. Introduction 
Cisplatin or cis-diamminedichloroplatinum II (CDDP) was approved by FDA in 1978, to treat 
testicular and bladder cancer (Galluzzi et al., 2012). Currently, CDDP is also used as a first-
line treatment for a broad range of solid tumors such as ovarian, cervical, head and neck, 
esophageal and lung (Rocha et al., 2014; Todd and Lippard, 2010) and  as an adjuvant therapy 
in recurrent glioblastoma (GBM) (Bent, van den, Hegi and Stupp, 2006; Brandes et al., 2004). 
Nevertheless, CDDP-doses are restricted by the resulting side-effects, which includes 
nephrotoxicity (Miller et al., 2010) and neurotoxicity (Amptoulach and Tsavaris, 2011). 
Aquated CDDP anti-cancer activity has been described as resulting from its ability to bind to 
nuclear DNA (El-khateeb et al., 1999), and form CDDP-DNA adducts through intrastrand or 
interstrand DNA cross-links (Eastman, 1987), which disrupt the structure of the DNA 
molecule, leading to cell-cycle arrest (Wang, D. and Lippard, 2005). Since, during the cell 
cycle arrest, CDDP adducts can be recognized and removed by multiple repair pathways 
(Wang, D. and Lippard, 2005), namely by nucleotide excision repair (NER) (Martin et al., 
2008; Rabik and Dolan, 2007), the success of CDDP is also limited by chemotherapy-
refractory mechanisms. However, if DNA damage exceeds the repair capacity, cell death 
supervenes (Galluzzi et al., 2012; Wang, D. and Lippard, 2005). In this context, since 
mitochondrial DNA (mtDNA) lacks NER (Cullen et al., 2007; Singh and Maniccia-bozzo, 
1990) and mitochondria play a central role in cell death mechanisms (Fulda et al., 2010), 
mtDNA emerges as a promising alternative cellular target for CDDP. Additionally, mtDNA 
is significantly more susceptible than nuclear DNA (ncDNA) to DNA-binding drugs, due to 
the lack of histones (Preston et al., 2001). 
Noteworthy, mitochondria are surrounded by a double-membrane that restricts the access 
of a wide range of ions and molecules to their interior. Therefore, there is a need for 
designing vectors that can surpass this barrier, in order to aid drugs to enter into 
mitochondrial matrix, when this is the local they exert their activity, namely targeting 
mtDNA (Smith et al., 2012). The most commonly used mitochondrial-targeting vectors 
involve the linkage of non-mitochondrial molecules to triphenylphosphonium cation (TTP) 
(Murphy, 2008), mitochondria-penetrating peptides (MMP) (Horton et al., 2008) or 
mitochondrial targeting sequences (MTS) (Omura, 1998), taking advantage of the 
mitochondrial membrane potential (in the case of TTP and MMP) or the mitochondrial 
protein-import machinery (in the case of  MTS) (Murphy, 1997). Additionally, cationic gemini 
surfactants, which are self-assembling molecules composed of two hydrocarbon chains (tails), 
two cationic headgroups and a spacer of diverse nature (Littau, 1996; Menger, F and Littau, 
1993; Menger, Fredric and Keiper, 2000), have recently shown to mediate efficient delivery 
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of plasmid DNA into mitochondria, and promote mitochondrial gene expression in HeLa 
cells (Cardoso et al., 2015b). 
In the present work, cationic gemini surfactants derived from the amino acid serine (Figure 
5.1) were evaluated regarding their ability to deliver a plasmid of mtDNA (pmtDNA) 
encoding GFP (pmtGFP), that is specifically translated by mitochondrial machinery (Lyrawati 
et al., 2011), into mitochondria of human recurrent GBM cells (DBTRG-05MG). The 
formulation that showed the highest efficiency in promoting GFP expression in 
mitochondria, without causing a pronounced cytotoxicity, was used to concomitantly deliver 
CDDP previously intercalated in pmtDNA. Interestingly, our data demonstrated that CDDP 
benefits from being delivered in the complexed form, i.e. intercalated in pmtDNA, and 
formulated in a gemini surfactant-based complex, leading to a higher decrease of cell viability 
and proliferation and a more efficient arrest of cell cycle in the S phase than CDDP 
administered in the free form, at the same concentration.  
 
 
Figure 5.1 - Schematic representation of the general structure of serine-derived gemini 
surfactants used in this work ((mSer)2N5 with m= 12, 14, 16 and 18). 
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5.3. Materials and methods 
Serine-derived gemini surfactants were synthesized by the method reported by Silva (Silva et 
al., 2012) and purified by column chromatography. The purity of the compounds was 
assessed by NMR and mass spectrometry, and the obtained cmc values revealed to be 
similar to those already reported in the literature (Burrows et al., 2007; Zana, 2002). 
The lipids 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE) and cholesterol (Chol) 
were purchased from Avanti Polar Lipids (Alabaster, AL). 
Plasmid DNA (pDNA) encoding nuclear GFP (pEGFP-C1, herein designated pncGFP) was 
obtained from Clontech (CA, USA) and plasmid DNA encoding mitochondrial GFP 
(pmtGFP) was synthesized and kindly provided by Prof. Diana Lyrawati, Brawijaya University 
(East Java, Indonesia). 
Cisplatin (CDDP) and DMSO (used to prepare CDDP stock solution) were acquired from 
Sigma (Germany). 
 
Cells and culturing conditions  
The human recurrent glioblastoma cell line DBTRG-05MG, kindly provided by Dr. 
Massimiliano Salerno (Siena Biotech, Italy), was maintained in culture at 37º C, under a 
humidified atmosphere containing 5% CO2. DBTRG-05MG cells were grown in monolayer in 
Roswell Park Memorial Institute 1640 (RPMI, Sigma, R4130) medium, supplemented with 
10% (v/v) heat-inactivated fetal bovine serum (FBS; Sigma, St. Louis, MO, USA), 100 units/mL 
penicillin (Sigma) and 100 µg/mL streptomycin (Sigma) and were detached using enzyme-free 
cell dissociation buffer at 50–70% confluence. For flow cytometry, DBTRG-05MG cells were 
plated at a density of 6x104 cells/well, in 1 mL of complete medium supplemented with FBS 
(10% v/v), in 12-well cell culture plates. For the Alamar blue and sulforhodamine B assays, 
cells were seeded at a density of 5x103 cells/well, in 100 µL of complete medium, in 96-well 
plates.  
 
Preparation of binary (gemini/pDNA) and ternary (gemini/pDNA/helper lipids) 
gemini surfactant-based complexes 
Gemini surfactant-based complexes were prepared as previously described (Cardoso et al., 
2014). Briefly, an aqueous solution of gemini surfactant was prepared at a concentration of 
0.5 mM and filtered through 0.22 μm pore-diameter filters (Schleicher & Schuell, BioScience, 
Germany). Binary complexes were prepared by mixing an aliquot of gemini solution in HBS 
with a constant amount of pDNA encoding GFP (pncGFP or pmtGFP to promote nuclear or 
mitochondrial GFP expression, respectively), in order to obtain the desired 
80 
 
surfactant/pDNA (+/-) charge ratios, followed by incubation at room temperature for 30 
min. To produce ternary complexes, a suspension of MLVs composed of DOPE:Chol (2:1 
molar ratio) was previously prepared by mixing, at this molar ratio, the helper lipids (HL) 
DOPE and Chol dissolved in chloroform. The lipid mixture was dried under vacuum in a 
rotatory evaporator, and the lipid film was hydrated with HBS (pH 11.0) to a final lipid 
concentration of 0.5 mM. The resulting multilamellar vesicles (MLV) were then sonicated for 
3 min, in a sonication bath, and added to surfactant/pDNA complexes previously incubated 
for 15 min at room temperature, in order to obtain the desired surfactant/HL molar ratios, 
followed by a further 15 min incubation. 
 
Preparation of gemini surfactant-based complexes containing cisplatin 
For the preparation of gemini/pDNA/CDDP complexes, a constant amount of plasmid DNA 
(1 µg/mL) was mixed with a solution of CDDP in HBS at different concentrations (4, 8 and 
16 µM). The mixture was left incubating for 10 min to promote association of the plasmid 
DNA with CDDP and then added to the gemini surfactant, to obtain the 8/1 
surfactant/pDNA (+/-) charge ratio. After an incubation period of 30 min, at room 
temperature, complexes were added to the cells. 
 
Cell transfection 
Twenty-four hours after plating, cell medium was replaced with fresh medium (serum-free 
OptiMEM medium). Gemini surfactant-based complexes, prepared at different (+/-) charge 
ratios and containing pDNA encoding GFP, were added to the cells in order to obtain a final 
pDNA concentration of 1 µg/mL. Following 4 h incubation (in 5% CO2, at 37 °C), the 
medium was replaced with fresh medium containing FBS (10% v/v) and antibiotics. 
  
Cell incubation with the drugs  
Twenty-four hours after plating, RPMI medium was replaced with OptiMEM, and CDDP, 
prepared in HBS, was added to 96-well plates to yield the final concentrations of 2, 4, 8, 16, 
31, 62.5, 125, 250, 500, 1000 μM. After 4 h of incubation, CDDP-containing medium was 
replaced with fresh RPMI medium. 
 
Evaluation of cell viability 
Cell viability was assessed by a modified Alamar blue assay, as previously described (Konopka 
et al., 1996). Briefly, an appropriate volume of resazurin dye (10% v/v) in RPMI medium was 
added to 12-well or 96-well culture plates. After color development, 150 µL of supernatant 
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were collected from each well, transferred to clear 96-well plates, and the absorbance was 
measured in a SPECTRAmax PLUS 384 spectrophotometer (Molecular Devices, Union City, 
CA), at 570 and 600 nm. Cell viability (as a percentage of control cells) was calculated 
according to the equation: 
 
Cell viability (% of control) = [(A570 – A600)/(A'570 – A'600)] x100 
 
where A570 and A600 are the absorbances of the treated cells, and A’570  and A’600 are 
those of the control (nontreated cells), at the indicated wavelengths. 
 
Evaluation of cell proliferation 
The sulforhodamine B assay was performed as previously described (Vichai and Kirtikara, 
2006). Briefly, immediately or 24, 48, 72 and 96 h after treatment with CDDP, cells were 
fixed by adding 100 µL of a 1% solution of acetic acid in methanol to each well, followed by 1 
h incubation at -20 ºC. Cells were then rinsed and left to dry at 37 ºC, for 20 min, before 
being incubated with 200 µL of 0.05% SRB staining solution containing 1% acetic acid, for 1 h 
at 37 ºC. To remove the unbound dye, cells were washed several times with a 1% solution 
of acetic acid in Milli-Q water and, then, left to dry at 37 ºC, for 20 min. The protein-bound 
dye was solubilized in 10 mM Tris buffer (pH 10) for 15 min, under gentle agitation, and the 
absorbance was measured at 540 nm in a microplate reader (SPECTRAmax PLUS 384, 
Molecular Devices, Union City, CA). 
 
Evaluation of transfection efficiency 
Forty-eight hours after transfection, cells were detached using enzyme-free cell dissociation 
buffer (5 min, at room temperature). Cells were then washed by centrifugation (200 g, 4 ºC, 
5 min) in 950 µL of ice-cold PBS and the resulting pellets were resuspended in 200 µL of ice-
cold PBS. The cell suspensions were immediately analyzed by flow cytometry using a FACS-
Calibur flow cytometer (BD Biosciences, San Jose, CA). To discriminate viable and dead cells 
and to exclude doublets, cells were appropriately gated by forward/side scattering and from 
a total of 10,000 events. Data were stored and analyzed using CellQuest software. 
 
Cell cycle analysis 
Twenty-four hours after cells were seeded in 12-well plates, the medium was replaced with 
serum-free medium and cells were transfected with (18Ser)2N5/pDNA or 
(18Ser)2N5/pDNA/CDDP complexes (at 8 µM CDDP) or treated with free CDDP, at the 
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same concentration. After 4 h of incubation, the medium was replaced with complete RPMI 
medium and, forty-eight hours later, cells were detached using enzyme-free cell dissociation 
buffer (10 min, at room temperature) and washed by centrifugation (300 g, 4 ºC, 5 min) with 
ice-cold PBS. The supernatant was discarded and cells were fixed by slowly adding 200 μL of 
70% ethanol, while vortexing the mixture at low speed. After 24 h incubation at 4 ºC, cells 
were centrifuged to remove ethanol, and washed once with 2% BSA in PBS. The resulting 
cell pellet was resuspended in 400 µL of propidium iodide/RNAse solution (Immunostep, 
Salamanca, Spain). After 15 min incubation under dark at room temperature, cell suspensions 
were immediately analyzed by flow cytometry using a FACS-Calibur flow cytometer (BD 
Biosciences, San Jose, CA). To discriminate viable and dead cells and to exclude doublets, 
cells were appropriately gated by forward/side scattering. Data were collected from at least 
10,000 single cell events, stored in CellQuest software and analyzed using ModFit LT 3.0.  
 
Statistical analysis  
Data are presented as mean ± SD of at least three independent experiments. The 
significance of the results was statistically analyzed by one-way analysis of variance (ANOVA) 
with Tukey's multiple pairwise comparison, unless stated otherwise. Statistical significance 
was set at p < 0.05. 
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5.4. Results 
5.4.1. Transfection Efficiency and Cytotoxicity of Gemini Surfactant-Based 
Complexes Carrying pmtGFP 
Aiming at selecting an efficient vector for pmtDNA, serine-derived gemini surfactants with 
different hydrocarbon chain lengths (m=12, 14, 16 and 18) were evaluated regarding their 
ability to mediate mitochondrial expression of GFP, in human recurrent GBM cells (DBTRG-
05MG). In parallel, the cell viability was assessed in order to select the formulation that 
encompasses both the highest transfection efficiency and the lowest cytotoxicity. As 
observed in Figure 5.2, the highest levels of GFP expression were obtained with complexes 
displaying the highest (+/-) charge ratio assayed (12/1), regardless of the serine-derived 
gemini surfactant used for their generation. However, complexes prepared at this (+/-) 
charge ratio exerted severe effects on cell viability, the reason why they were discarded. At 
the (+/-) charge ratio of 8/1, the complexes based on the gemini surfactant with 18C-tails 
showed the highest efficiency in delivering pmtGFP into mitochondria, inducing the 
expression of GFP protein in 20% of viable cells without causing a severe reduction of cell 
viability. A further decrease of the (+/-) charge ratio to 4/1 in these complexes did not 
induce a significant decrease of the cytotoxicity (Figure 5.3A) and significantly reduced their 
transfection ability (Figure 5.3B). In order to improve the transfection capacity of 
(18Ser)2N5/pmtGFP complexes (herein designated binary complexes), preformed vesicles of 
the helper lipids DOPE and Chol at the 2:1 molar ratio (HL) were added to the binary 
complexes (as described in Material and Methods section), resulting in the formation of 
ternary complexes with different HL:gemini surfactant molar ratios (1:1, 2:1 and 4:1). Figure 
5.3 shows that cell viability decreased with the addition of HL to the complexes, except 
when they were prepared at 12/1 (+/-) charge ratio. Additionally, HL reduced the efficiency 
of the complexes to mediate gene expression at all (+/-) charge ratios, being, hence, the 
binary complexes the most effective formulations. Consequently, (18Ser)2N5/pmtGFP 
complexes, at 8/1 (+/-) charge ratio, which ally a moderate transfection efficiency (20% of 
transfected cells) with low cytotoxicity (above 80% of cell viability), were selected for the 
subsequent experiments. 
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Figure 5.2 - Cell viability (A) and transfection efficiency (B) promoted by complexes of 
pmtGFP and serine-derived gemini surfactants with different tail length, as indicated in the 
figure. Cells were incubated for 4 h with the complexes prepared at the 8/1 (white) and 12/1 
(gray) (+/−) charge ratios, after which the complex-containing medium was replaced by fresh 
complete medium. The cells were allowed to further incubate for 44 h. After this period, cell 
viability was assessed using a modified Alamar blue assay and transfection efficiency was 
evaluated by flow cytometry as the percentage of transfected viable cells. The results are 
presented as a percentage of the control (nontreated cells) and represent the mean ± SD 
obtained from two independent experiments. 
 
 
Figure 5.3 - Cell viability (A) and transfection efficiency (B) promoted by (18Ser)2N5-based 
complexes in the presence and absence of  helper lipids (HL) at HL:(18Ser)2N5 molar ratios, 
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as indicated in the figure. Cells were incubated for 4 h with the complexes prepared at the 
4/1 (white), 8/1 (gray) and 12/1 (black) (+/−) charge ratios, after which the complex-
containing medium was replaced by fresh complete medium. The cells were allowed to 
further incubate for 44 h. After this period, cell viability was assessed using a modified 
Alamar blue assay and transfection efficiency was evaluated by flow cytometry as the 
percentage of transfected viable cells. The results are presented as a percentage of the 
control (nontreated cells) and represent the mean ± SD obtained from three independent 
experiments. 
 
5.4.2. Impact of CDDP and (18Ser)2N5/pmtGFP/CDDP on DBTRG-05MG 
cell viability and proliferation 
To evaluate whether CDDP formulated in (18Ser)2N5/pmtGFP complexes, at 8/1 (+/-) 
charge ratio, would be more effective than free CDDP in decreasing the viability of DBTRG-
05MG GBM cells, cell viability was assessed by Alamar blue assay 48 h after treatment with 
CDDP, either complexed or in its free form. Initial experiments were performed by 
exposing DBTRG-05MG cells to different drug concentrations, for 4 h (Figure 5.4), in order 
to determine the optimal concentration of the drug to be used in the assay. As shown, a 
moderate decrease in cell viability (c.a. 20%) was observed 48 h post-treatment at the 
concentrations 4, 8 and 16 µM (indicated in the figure in blue color), which were selected 
for the subsequent experiments. 
 
 
Figure 5.4 - Effect of CDDP on DBTRG-05MG cell viability. Twenty-four hours after 
plating, cells were exposed to increasing CDDP concentrations, in serum-free medium. After 
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4 h incubation, CDDP containing medium was replaced with fresh complete medium and, 24 
(gray line) and 48 h (black line) later, cell viability was assessed by the Alamar blue assay. The 
results are presented as a percentage of the control (nontreated cells) and represent the 
mean ± SD obtained from three independent experiments. The blue points indicate the 
values of cell viability at the concentrations of CDDP (4, 8 and 16 µM) that were selected 
for the subsequent experiment. 
 
Figure 5.5 allows to comparing the impact of complexed and free CDDP on the viability of 
DBTRG-05MG cells, 48 h after treatment. As observed, the percentage of viable cells 
decreased when CDDP at 4 and 8 µM was carried by (18Ser)2N5/pmtGFP/CDDP 
complexes, this decrease being much more pronounced than that observed when cells were 
exposed to free CDDP at the same concentrations. At the highest CDDP concentration 
assayed (16 µM), the percentages of viable cells exposed to complexed or free CDDP did 
not show a statistically significant difference. The next experiments were, hence, performed 
with CDDP at 8 µM.  
 
 
Figure 5.5 - Effect of complexed and free CDDP on DBTRG-05MG cell viability. Viability of 
DBTRG-05MG cells was assessed by the Alamar blue assay, 48 h after transfection with 
(18Ser)2N5/pmtGFP (dotted bar) or (18Ser)2N5/pmtGFP/CDDP complexes containing 4, 8 
and 16 µM CDDP (white bars) or after treatment with free CDDP (black bars), at the same 
concentrations. Cells were incubated with the different treatments for 4 h, in serum-free 
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medium. The results are presented as a percentage of the control (nontreated cells) and 
represent the mean ± SD obtained from three independent experiments. The viability of 
cells transfected with complexed CDDP (white bars) were compared with that of cells 
treated with the corresponding concentrations of free CDDP (black bars) (* p<0.05). 
 
In order to compare the effects exerted by complexed and free CDDP at 8 µM on cell 
proliferation, a sulforhodamine B (SRB) assay was performed to determine the cellular 
protein content, at different time points, for a 5 day-period after treatment (Figure 5.6). The 
increase of protein mass, which reflects the increase in cell density, follows the same trend 
in cultures of nontreated cells and cells treated with free CDDP, although the latter 
displayed a slower growth rate from 48 h post-treatment and the yield of protein mass at 
the 96 h time point was significantly lower in this culture than in the culture of nontreated 
cells. However, cells treated with the complexes containing CDDP showed a lag phase 
(about 24 h), and 48 h post-treatment cell growth apparently initiated a stationary phase. 
Remarkably, the yield of protein mass 96 h post-treatment was nearly half of that of 
nontreated cells and noticeably lower than the one observed when cells were treated with 
free CDDP, stressing the advantage of delivering CDDP via gemini surfactant-based 
complexes to promote efficient inhibition of cell proliferation.  
 
 
Figure 5.6 - Growth curves of DBTRG-05MG cells, as assessed by sulforhodamine B (SRB) 
assay. Proliferation of cells transfected with (18Ser)2N5/pmtGFP/CDDP complexes 
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containing 8 µM CDDP (○) or treated with 8 µM free CDDP (●) is compared with that of 
control cells (nontransfected and nontreated with CDDP) (■). Cell density was measured at 
different time points (4, 24, 48, 72 and 96 h) after treatment with CDDP. Density of control 
cells was measured at the same time points for direct comparison. Proliferation results for 
each condition are expressed as percentage of the respective cell density at the first time 
point (set at 100%; T = 0) and represent the mean ± SD obtained from three independent 
experiments. Pairwise comparisons were performed between each condition and nontreated 
cells, 96 h post-treatment (* p<0.05). 
 
5.4.3. Impact of CDDP and (18Ser)2N5/pmtGFP/CDDP on DBTRG-05MG 
cell cycle  
The distribution of DBTRG-05MG cells along the different phases of the cell cycle (G0/G1, S 
and G2/M) was analyzed 48 h post-treatment with complexed and free CDDP (Figure 5.7).  
As observed, 60% of nontreated cells, collected at the same time as those subjected to 4 h 
treatment with complexed or free CDDP, were found to be in the G0/G1 phase, and a small 
amount (c.a. 7%) in the G2/M phase. As compared to nontreated cells, cells transfected with 
complexes devoid of CDDP presented a very similar pattern of distribution along the cell 
cycle phases. However, cell treatment with complexes containing CDDP or with free CDDP 
resulted in a significant reduction in the percentage of cells in the G0/G1 phase (to around 
one third) as compared to nontreated cells. Moreover, the percentage of cells in the S phase 
drastically increased, particularly in the case of cells treated with the complexed CDDP, the 
majority of which (c.a. 70%) were arrested in the S phase. In contrast, the free CDDP 
allowed a significant amount of cells to pass to the G2/M phase, as compared to nontreated 
cells or cells transfected with complexes in the presence or absence of CDDP. 
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Figure 5.7 - Distribution of DBTRG-05MG cells along the phases of cell cycle. The cell 
cycle phases, G0/G1 (   ), S (   ) and G2/M (   ) are indicted in the figure. Forty-eight hours 
after transfection with complexes of (18Ser)2N5/pmtGFP in the absence or presence of 8 
µM of CDDP, cells were fixed and cell cycle was analyzed by flow cytometry. Nontreated 
cells and cells treated with 8 µM free CDDP are shown as controls. The results represent 
the mean ± SD obtained from three independent experiments. Pairwise comparisons were 
performed between each condition and nontreated cells (** p<0.01; *** p<0.001) and 
between the complexed CDDP and the free CDDP conditions (# p<0.05, using the unpaired 
t-test). 
 
 
5.4.4. Impact of CDDP Added to (18Ser)2N5/pGFP Complexes on 
Transfection Efficiency  
To investigate whether the association of CDDP with the plasmid DNA could impair the 
efficiency of the delivery system, the levels of mitochondrial GFP expression promoted by 
(18Ser)2N5/pmtGFP and (18Ser)2N5/pmtGFP/CDDP complexes were analyzed by flow 
cytometry. Additionally, to clarify whether (18Ser)2N5-based complexes would also promote 
delivery of pDNA into the nucleus, their efficiency to mediate the expression of a pncDNA 
encoding GFP (pncGFP) was evaluated. Figure 5.8 shows the transfection efficiency of 
complexes of (18Ser)2N5 with pmtGFP or pncGFP, in the absence or in the presence of 8 
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µM CDDP. The percentage of transfected cells with (18Ser)2N5/pmtGFP was statistically 
different from that of cells transfected with (18Ser)2N5/pncGFP, which may indicate that the 
formulation has a certain mitochondrial tropism. Surprisingly, when CDDP was included in 
the delivery system, the percentage of transfected cells increased (to about 33%), as 
compared to that of cells transfected in the absence of CDDP (20% and 7%, when pmtGFP 
and pncGFP were used, respectively). Therefore, (18Ser)2N5/pDNA/CDDP complexes were 
able to promote gene expression and, hence, CDDP delivery, both in mitochondria and 
nucleus.  
 
Figure 5.8 - Transfection efficiency of (18Ser)2N5-based complexes carrying mitochondrial 
or nuclear plasmid in the absence or in the presence of CDDP. The complexes containing 
pmtGFP (white bars) or pncGFP (gray bars) were prepared at the 8/1 (+/-) charge ratio, in 
the absence or presence of 8 µM CDDP. The results are presented as a percentage of the 
control (nontreated cells) and represent the mean ± SD obtained from three independent 
experiments. Pairwise comparisons were performed between formulations prepared with 
the same plasmid DNA containing CDDP vs. those not containing CDDP (*** p<0.001) and 
between the formulation prepared with pmtGFP vs. that with pncGFP, in the absence of 
CDDP (## p<0.01, using the unpaired t-test). 
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5.5. Discussion 
The efficacy of the anti-cancer drug cisplatin (CDDP) is considerably restricted by the 
emergence of secondary effects and the intrinsic drug resistance, resulting from DNA repair 
mechanisms. Hence, the DNA of mitochondria becomes an attractive target for this drug 
owing to mtDNA susceptibility to chemical attack, mainly because of the lack of protective 
histones and the limited ability of mitochondria to repair the damaged DNA  (Cullen et al., 
2007; Preston et al., 2001; Singh and Maniccia-bozzo, 1990). 
Recent studies in our laboratory demonstrated the capacity of gemini-based complexes 
carrying a plasmid DNA encoding GFP, which is specifically translated by mitochondrial 
machinery (Lyrawati et al., 2011), to promote the expression of this protein in mitochondria 
of HeLa cells 4. In the present work, a formulation based on the cationic serine-derived 
gemini surfactant (18Ser)2N5, previously selected because of its efficiency in delivering 
pmtDNA into mitochondria of human recurrent GBM cells (DBTRG-05MG), was employed 
to transport CDDP to mitochondria of these cells, through its intercalation into pmtDNA 
carried by the surfactant. The main objective of this approach is to benefit from the ability of 
(18Ser)2N5/pmtDNA formulation to target mitochondria (inferred from the expression of 
GFP in mitochondria) in order to carry CDDP to the proximity of mtDNA with two 
predictable advantages: firstly, the reduction of the anti-cancer drug concentration required 
to promote a cytostatic effect (arresting cell cycle) or to drive cells to apoptosis, obviating 
also the extrusion of the drug by cell membrane ABC transporters (Galluzzi et al., 2012); 
secondly, the possibility of a concomitant transport of a therapeutic gene to mitochondria, 
rendering these organelles more susceptible to the damage induced by CDDP in the 
mtDNA. 
Although the serine-derived gemini surfactant with 18C hydrocarbon chains showed to 
promote gene expression in mitochondria in a moderate percentage of viable cells, 
experiments were conducted aiming at improving the efficiency of (18Ser)2N5 to mediate 
GFP expression in these organelles, by adding to the formulation the helper lipids (HL) 
DOPE and Chol at different gemini surfactant/HL molar ratios (Figure 5.3). The role of these 
lipids in enhancing the transfection activity of conventional and serine-derived surfactants has 
been demonstrated in our laboratory (Cardoso et al., 2014, 2015b), and attributed to the 
propensity of DOPE to destabilize endosomal membrane (Hafez and Cullis, 2001; Hui et al., 
1996; Koltover et al., 1998; Siegel and Epand, 1997; Zuhorn et al., 2005), and the potential of 
Chol to stabilize the complexes (Crook et al., 1998; Faneca et al., 2002; Maslov and Zenkova, 
2011; Semple et al., 1996). Nevertheless, HL addition to (18Ser)2N5/pmtDNA complexes 
showed a negative impact on both the viability of DBTRG-05MG cells and the efficiency of 
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GFP expression in mitochondria, in accordance with previous studies in HeLa cells, which 
revealed a decrease in the transfection activity of complexes composed of pncDNA and 
(18Ser)2N5 in the presence of HL (Cardoso et al., 2015a). Since the Zeta potential of gemini 
surfactant-based complexes was shown to change from positive to negative upon addition of 
HL (Cardoso et al., 2015a), and mitochondria display a highly negative transmembrane 
potential, thus counteracting the entry of negative particles into the matrix, the loss of 
transfection efficiency of the (18Ser)2N5/pmtDNA complexes, when combined with HL, can 
be putatively attributed to a negative Zeta potential. Indeed, the transfection efficiency of the 
binary complexes showed to increase with increasing (+/−) charge ratios (Figure 5.2), 
supporting the need of an overall positive charge to induce mitochondrial gene expression. 
Moreover, the improvement of the transfection upon CDDP association to the delivery 
system (Figure 5.8) may be explained by the increase in the overall positive charge of the 
complexes conferred by the drug, which becomes positively charged in the intracellular 
environment (Cullen et al., 2007; Rocha et al., 2014). 
The advantage of delivering CDDP formulated in (18Ser)2N5/pmtDNA was evaluated by 
comparing its impact on DBTRG-05MG cell viability and proliferation with that resulting 
from cell exposure to free CDDP. In fact, when cells were exposed to complexed CDDP, a 
more drastic decrease of viability was achieved as compared to that observed for cells 
treated with free CDDP at the same concentrations (Figure 5.5). Indeed, the presence of 8 
µM of CDDP in gemini surfactant-based complexes promoted an inhibition of cell viability 
(c.a. 30%), which was only achieved by free CDDP at 16 µM (i.e. twice the concentration). 
Nevertheless, the capacity of the (18Ser)2N5/pmtDNA formulation to carry CDDP seems to 
be dose-limited, since complexed and free CDDP, at the concentration of 16 µM, did not 
show significantly different effects on cell viability, likely because pmtGFP achieved CDDP-
saturation at this concentration. On the other hand, cellular protein content, as assessed by 
the SRB assay, which reflects the number of cells in culture at each time point (Papazisis et 
al., 1997), clearly revealed a decrease of cell growth rate upon 48 h of treatment with CDDP 
formulated in the complexes (Figure 5.6). In contrast, cells treated with free CDDP for the 
same period of time and nontreated cells exhibited an increase of the growth rate. 
Remarkably, at the 96 h time point, the cell density attained by cultures grown in the 
presence of complexed CDDP was approximately half that displayed by nontreated cells and 
considerably lower than that found for cells treated with free CDDP. The limited growth 
observed in the presence of complexed CDDP seems to correlate well with the 
accumulation of cells in the S phase, which were apparently prevented from proceeding to 
the G2/M phase of the cell cycle (Figure 5.7). Interestingly, the percentage of cells arrested in 
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the S phase was much lower in cultures treated with free CDDP, a significant number of 
cells proceeding to the next phase of the cell cycle (G2/M) being observed under these 
conditions. 
Although we cannot definitely attribute the more severe cytotoxicity induced by complexed 
CDDP, as compared with that of free CDDP, to a higher accessibility to mtDNA or to a 
lower extrusion of the complexed drug by the cells, our work emphasizes the potential of 
gemini surfactant-based formulations to efficiently deliver anti-cancer drugs, which deserves 
to be explored towards an effective therapeutic approach. On the other hand, this study 
opens windows to a multimodal therapeutic approach against GBM, which allies the gene 
therapy addressing nuclear and/or mitochondrial genes with key-roles in cancer progression 
to the use of conventional pharmacological drugs, thus allowing to reduce their therapeutic 
concentrations and, hence, to attenuate their potential side-effects. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 6 
 
 Concluding remarks and future perspectives  
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Concluding remarks and future perspectives  
The chemoresistance is one of the most remarkable features of GBM, being directly 
responsible for GBM recurrence upon surgical resection. The overexpression of ABC 
transporters, which promote the extrusion of chemotherapeutics to the extracellular space, 
and apoptosis resistance constitute inherent and acquired properties of GBM cells. 
Additionally, some drugs, such as those forming DNA adducts, may induce mechanisms of 
DNA repair, which counteract the damage promoted by such drugs. 
In this context, the present study opens windows for new strategies, based on gene therapy, 
that increase GBM cell susceptibility to the action of anti-cancer drugs.  
Employing a very well established cell model of human GBM (U87 cells), it was 
demonstrated that downregulation of the inhibitor-of-apoptosis protein survivin sensitized 
those cells to the toxicity exerted by the chemotherapeutics temozolomide and etoposide.  
On the other hand, treatment of cells derived from patients presenting a recurrent GBM 
(DBTRG-05MG cells) with CDDP showed to benefit from drug association with a plasmid of 
mitochondrial DNA formulated in gemini surfactant-based complexes. Moreover, the 
plasmid DNA associated with CDDP did not lose its capacity to promote gene expression. 
Therefore, co-delivery of CDDP and a therapeutic gene emerges as a powerful strategy to 
fight GBM cell chemoresistance. 
Importantly, the successful application of the two strategies (survivin downregulation and 
complex-mediated CDDP delivery) was achieved taking advantage of the versatility and 
potential of cationic gemini surfactants as drug delivery systems. 
Altogether, data provided in this study pave the way for the development of multimodal 
therapies for GBM, which combine the administration of chemotherapeutics with strategies 
that render cells more sensitive to drugs, allowing to reduce drug therapeutic doses and, 
hence, to prevent non-specific toxicity. 
 
However, further studies should be addressed to elucidate the mechanisms through which 
the delivery of CDDP formulated in complexes of pDNA and gemini surfactant, targeting 
mitochondria, ensures a more efficient inhibition of cell proliferation and cell cycle 
progression. Several possibilities can be envisaged: firstly, the cytotoxic activity of CDDP 
resulting from the formation of DNA adducts can be more severe when targeting 
mitochondrial genome, as compared to nuclear genome, due to the less efficient mechanisms 
of DNA repair in mitochondria; secondly, CDDP carried to mitochondria by surfactant-
based complexes may escape to the action of ABC efflux pumps, which address cytosolic 
substrates. In this context, the development of gemini surfactant-based delivery systems with 
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an evident tropism to mitochondria could be useful to further improve CDDP therapeutic 
activity.  
Due to the relatively low unspecific toxicity exerted by gemini surfactants in GBM cells, a 
dual delivery of anti-survivin siRNAs in cytoplasm and plasmid mitochondrial DNA 
associated with CDDP in mitochondria, mediated by distinct gemini surfactant-based systems 
with adequate delivery features, can also be envisaged. On the other hand, the association to 
the surfactant-based formulations of targeting peptides such as chlorotoxin, which binds 
specifically to glioma cells, could ensure a substantial reduction of drug side-effects in healthy 
cells. 
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